

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00		A1	(11) International Publication Number: WO 99/29728
			(43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291		(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US).	
(22) International Filing Date: 11 December 1998 (11.12.98)			
(30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97)			
(71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US).			
(72) Inventors; and		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).			
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES			
(57) Abstract <p>The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see *generally* Coutinho, 1991, Immune System, *Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , τ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravecz et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	HN-4		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX3C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clonetech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, *i.e.*, a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, *Protein Research Foundation*, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6CKine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, *i.e.*, a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokine(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 supra)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1 _{III}B was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{III}B. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIB} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same dose of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DTH gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
42. The composition of claim 33, wherein the chemokine is a human chemokine.
43. The composition of claim 33, wherein the antigen is an HIV antigen.
44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.

46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA	GGACAGAGC	ATG	GCT	CGC	CTA	CAG	ACT	GCA	CTC	CTG	GTT	GTC	52			
Met Ala Arg Leu Gln Thr Ala Leu Val Val																
-24 -20 -15																
CTC	GTC	CTC	CTT	GCT	GTG	GCG	CTT	CAA	GCA	ACT	GAG	GCA	GGC	CCC	TAC	100
Leu	Val	Leu	Leu	Ala	Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	
-10 -5 1																
GGC	GCC	AAC	ATG	GAA	GAC	AGC	GTC	TGC	TGC	CGT	GAT	TAC	GTC	CGT	TAC	148
Gly	Ala	Asn	Met	Glu	Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	
5 10 15																
CGT	CTG	CCC	CTG	CGC	GTG	GTG	AAA	CAC	TTC	TAC	TGG	ACC	TCA	GAC	TCC	196
Arg	Leu	Pro	Leu	Arg	Val	Val	Lys	His	Phe	Tyr	Trp	Thr	Ser	Asp	Ser	
20 25 30 35																
TGC	CCG	AGG	CCT	GGC	GTG	GTG	TTG	CTA	ACC	TTC	AGG	GAT	AAG	GAG	ATC	244
Cys	Pro	Arg	Pro	Gly	Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	
40 45 50																
TGT	GCC	GAT	CCC	AGA	GTG	CCC	TGG	GTG	AAG	ATG	ATT	CTC	AAT	AAG	CTG	292
Cys	Ala	Asp	Pro	Arg	Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	
55 60 65																

FIG. 1A-I

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	
GGAGCCCTAC CTCCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG	408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCAC TGCC	468
ATCTCCCCC TGACCCCTCT AACCCTCCT CTGCCCTCCCT CCCTGCAGTC AGAGGGTCTT	528
GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCCACTGC CCTAAGCTGA	588
GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCCATCT CTGTCTCCAG	648
CCTGCCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCA ACCCATACTA	708
CACATCCCAC TTCTGGGTCT TTGCCCTGGA TGTGTGCTGAC ACTCAGAAAG TCCCACCACC	768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCAATGCTC GCCCAAGCAG CTGGTAATTC	828
CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCTC TTAATAACCC TAGTCACAGT	888
CTCCGCAGAT TCTTGGGATT TGGGGGTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG	948

FIG. 1A-2

SUBSTITUTE SHEET (RULE 26)

3/6

<u>GTTTCTAGCT</u>	<u>AAGTTACTCT</u>	<u>AGTCTCCAAG</u>	<u>CCTCTAGCAT</u>	<u>AGAGCACTGC</u>	<u>AGACAGGCC</u>	1008	
TGGCTCAGAA	TCAGAGCCCA	GAAAGTGGCT	GCAGACAAA	TCAATAAAC	TAATGTCCCT	1068	
CCCCCTCTCCC	TGCCAAAAGG	CAGTTACATA	TCAATACAGA	GACTCAAGGT	CACTAGAAAT	1128	
GGGCCAGCTG	GGTCAATGTG	AAGCCCCAAA	TTTGCCCAGA	TTCACCTTTC	TTCCCCCACT	1188	
CCCTTTT	TTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CGCTGGAGTG	1248	
CAATGGTGTG	GTCTTGGCTT	ATTGAAGCCT	CTGCCCTCCTG	GGTCAAGTG	ATTCTCTTGC	1308	
CTCAGCCTCC	TGAGTAGCTG	GGATTACAGG	TTCTCTGCTAC	CACGCCCAGC	TAATTTTGT	1368	
ATTTT	TAGTA	GAGACGAGGC	TTACACCATGT	TGGCCAGGCT	GGTCTCGAAC	TCCTGTCTCTC	1428
AGGTAATCCG	CCCACCTCAG	CCTCCCCAAAG	TGCTGGGATT	ACAGGCGTGA	GCCACAGTGC	1488	
CTGGCCCTCTT	CCCTCTCCCC	ACTGCCCCCCC	CCAACTTTTT	TTTTTTTTTTT	ATGGCAGGGT	1548	
CTCACTCTGT	CGCCCAGGCT	GGAGTGCAGT	GGCGTGATCT	CGGCTCACTA	CAACCTCGAC	1608	
CTCCTGGGT	CAAGTGATTC	TCCCACCCCA	GCCTCCCAAG	TAGCTGGGAT	TACAGGTGTG	1668	

FIG. 1A-3

<u>TGCCACTACG</u>	<u>GCTGGCTAAT</u>	<u>TTTTGTATTT</u>	<u>TTAGTAGAGA</u>	<u>CAGGTTTCAC</u>	<u>CATATTGGCC</u>	1728
AGGCTGTCT	TGAACTCCTG	ACCTCAAGTG	ATCCACCTTC	CTTGTGCTCC	CAAAGTGCTG	1788
AGATTACAGG	CGTGAGCTAT	CACACCCAGC	CTCCCCCTTT	TTTTCCCTAAT	AGGAGACTCC	1848
TGTACCTTTC	TTCGTTTTAC	CTATGTGTCG	TGTCGTGCTTA	CATTTCCTTC	TCCCCCTCAGG	1908
CTTTTTTTTG	GTGGTCCTCC	AACCTCCAAT	ACCCAGGCCT	GGCCTCTTCA	GAGTACCCCC	1968
CATTCCACTT	TCCCTGCCTC	CTTCCTTAAA	TAGCTGACAA	TCAAATTCAT	GCTATGGTGT	2028
GAAAGACTAC	CTTTGACTTG	GTATTATAAG	CTGGAGTTAT	ATATGTATTT	GAAAACAGAG	2088
TAAATACTTA	AGAGGCCAAA	TAGATGAATG	GAAGAATTTT	AGGAACTGTG	AGAGGGGGAC	2148
AAGGTGAAGC	TTTCCTGGCC	CTGGGAGGAA	GCTGGCTGTG	GTAGCGTAGC	GCTCTCTCTC	2208
TCTGTCTGTG	GCAGGAGCCA	AAGAGTAGGG	TGTAATTGAG	TGAAGGAATC	CTGGGTAGAG	2268
ACCATTCTCA	GGTGGTTGGG	CCAGGCTAAA	GACTGGGAGT	TGGTCTATC	TATGCCCTTTC	2328
TGGCTGATTT	TTGTAGAGAC	GGGGTTTTCG	CATGTTACCC	AGGCTGGTCT	CAAACTCCTG	2388

FIG. 1A-4

GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC	2448
TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTC ATACAGCAAG TATGGGACAG	2508
CAGTGTCCCA GGTAAGGAC ATAAATGTTA CAAGTGCTG GTCCTTCTG AGGGAGGCTG	2568
GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCCTGAA	2628
CCCAGCCTGA CAAATCACAG TGAGAAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT	2688
TGAAAGTGTG GGGAGTGACA CTGCCCTAGGC ATCCAGCTCA GTGTCAATCCA GGGCCTGTGT	2748
CCCTCCCGAA CCCAGGGTCA ACCTGCCCTGC CACAGGCACT AGAAGGACGA ATCTGCCCTAC	2808
TGCCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCCTCCTG TCCTGTCTCTT	2868
GCCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAAAATAGT AAAAAAATAA AAAA	2923

FIG. 1A-5

FIG. 1A

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

6/6

Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Leu	Val	Val	Leu	Val	Leu	Leu	Ala
-24				-20					-15					-10	
Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu
			-5					1				5			
Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Arg
		10				15					20				
Val	Lys	His	Phe	Tyr	Tyr	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly
25				30					35					40	
Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Arg
				45					50					55	
Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	Ser	Gln			
				60				65							

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCGGCCAG AAGCCTGTGC CAACTCTCTG 408
 CATTCCCTGA TCTCCATCCC TGTGGCTGTG ACCCTTGGTC ACCTCCGTGC TGTCAGTGCC 468
 ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT 528
 GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588
 GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
 CCTGCCCACT TCCTTTCATG AATGTTGGGT TCTAGCTCCC TGTCTCCAA ACCCATACTA 708
 CACATCCAC TTCTGGGTCT TTGCCTGGGA TGTGTCTGAC ACTCAGAAAG TCCCACCACC 768
 TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828
 CATTTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCTC TTAATAACCC TAGTCACAGT 888
 TCCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCACC TCCTCCACTAG TTGGACCAAG 948
 GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCC 1008
 TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAAC TAATGTCCCT 1068
 CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA TACTCAAGGT CACTAGAAAT 1128
 GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTACCTTTT TCCCCCACT 1188
 CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCAACCA CGCTGGAGTG 1248
 CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAGTG ATTCTCTTGC 1308
 CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCTGTCTAC CACGCCAGC TAATTTTTGT 1368
 ATTTTGTAGTA GAGACGAGGC TTCACCATGT TGCCAGGCT GGTCTCGAAC TCCTGTCTC 1428
 AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
 CTGGCCCTCT CCCTCTCCCC ACTGCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGGT 1548
 CTCACTCTGT CGCCAGGCT GGAGTGCAGT GCGGTGATCT CGGCTCACTA CAACCTCGAC 1608
 CTCCTGGGTT CAAGTGATTC TCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG 1668
 TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC 1728
 AGGCTGGTCT TGAACCTCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGTG 1788
 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCTAAT AGGAGACTCC 1848
 TGTACCTTTC TTCTGTTTAC CTATGTGTCG TGTCTGCTTA CATTTCTCTC TCCCCTCAGG 1908
 CTTTTTTTGG GTGGTCTCC AACCTCCAAT ACCCAGGCT GGCCTCTTCA GAGTACCCCC 1968
 CATTCCACTT TCCCTGCCTC CTCTCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT 2028
 GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAACAGAG 2088
 TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAAGTGTG AGAGGGGGAC 2148
 AAGGTGAAGC TTTCTGGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC 2208
 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAAATTGAG TGAAGGAATC CTGGGTAGAG 2268
 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC 2328
 TGGCTGATTT TTGTAGAGAC GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG 2388
 GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGTG GGATTACAGG CGTGAATCAC 2448
 TGCGCCTGCC TTCCTCTTCC TCTTGAGAAA TATCTTTTTC ATACAGCAAG TATGGGACAG 2508
 CAGTGTCCCA GGTAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTTCTG AGGGAGCCTG 2568
 GTGCCGCTCT GCAGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTT ACTCCTGAA 2628
 CCCAGCCTGA CAAATCAGAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT 2688
 TGAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTATCCA GGGCTGTGT 2748
 CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC 2808
 TGCCCATGAA CGGGGCCCTC AAGCGTCTG GGATCTCTT CTCCCTCCTG TCCTGTCTTT 2868
 GCCCCTCAGG ACTGCTGGAA AATAATCCTT TTAATAAGT AAAAAA 2923

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
 -24 -20 -15 -10
 Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
 -5 1 5
 Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
 10 15 20
 Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
 25 30 35 40
 Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
 45 50 55
 Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
 60 65

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines

Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA PRI 31-MAY-1997
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete
 cds.
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska,R., Chantry,D., Raport,C.J., Sozzani,S., Allavena,P.,
 Leviten,D., Mantovani,A. and Gray,P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant
 for monocytes, monocyte-derived dendritic cells, and natural
 killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska,R. and Gray,P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES
 source Location/Qualifiers
 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
 LPLRVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQ"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacataca ggacagagca tggctcgctt acagactgca ctcttggttg tctctgctct
 61 ccttgctgtg gcgcttcaag caactgaggg agggccctac ggcgcacaac tgggaagacag
 121 cgtctgctgc cgtgattacg tccgttaccg tctgcccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtgggtgtg ctaaccttca gggataagga
 241 gatctgtgcc gatccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctctccagg aaggetcagg agccctacct
 361 ccttgccatt atagctgttc cccgccagaa gcctgtgcca actctctgca ttccctgatc
 421 tccatccctg tggctgtcac ccttggtcac ctccgtgtg tcaactgccat ctcccccttg
 481 accctcttaa cccatcctct gctccctctc ctgcagtcag aggggtctgt tcccatcagg
 541 gattcccttg cttaaaccct tccatgactc cccactgccc taagctgagg tcagtctccc
 601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
 661 ccttcattga tgttgggttc tagctccctg ttctccaaac ccataactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaagtc ccaccactg cacatgtgta
 781 gccccaccag ccctccaagg cattgctcgc ccaagcagct ggtaattcca ttcatgttat
 841 tagatgtccc ctggccctct gtccctcttt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
1081 ccaaaaaggca gttacatata aatacagaga ctcaagggtca ctagaatgg gccagctggg
1141 tcaatgtgaa gcccacaaatt tgcccagatt cacccttctt cccccactcc cttttttttt
1201 tttttttttt tgagatggag tttcgctctt gtcacccacg ctggagtgca atggtgtggt
1261 cttggcttat tgaagcctct gccctcctggg ttcaagtgat tctcttgct cagcctcctg
1321 agtagctggg attacaggtt cctgctacca cgcccagcta atttttgtat ttttagtaga
1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtcctcag gtaatccgcc
1441 cacctcagcc tcccaaagtg ctgggattac aggcgtgagc cacagtgcct ggctctcttc
1501 ctctcccccac tgccccccc aacttttttt ttttttttat ggcaagggtc cactctgtcg
1561 cccaggctgg agtgagctgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta caggtgtgtg ccactacggc
1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctgtcttg
1741 aactcctgac ctcaagtgat ccaccttctt tgtgtccca aagtgtgag attacaggcg
1801 tgagctatca caccagcctt cccctttttt ttcttaatat gagactcctg tacctttctt
1861 cgtttttac atgtgtcgtg tctgcttaca ttctcttctt cctcagggt ttttttgggt
1921 ggtcctccaa cctccaatac ccaggcctgg cctcttcaga gtacccccca ttccactttc
1981 ctgtcctcct tccttaata gctgacaatc aaattcatgc tatggtgtga aagactacct
2041 ttgacttgg attataagct ggagttatat atgtatttga aaacagagta aatacttaag
2101 aggccaaata gatgaatgga agaatttttag gaactgtgag aggggggaca ggtgaagctt
2161 tcctggccct gggaggaagc tggctgtggt agcgtagcgc tctctctctc tgtctgtggc
2221 agggaccaa gagtaggggt taattgagtg aaggaatcct gggtagagac cattctcagg
2281 tgggtgggccc aggcataaaga ctgggagttg ggtctatcta tgcctttctg gctgattttt
2341 gtagagacgg ggttttgcca tgttaccacg gctggtctca aactcctggg ctcaagcgat
2401 cctcctggct cagcctccca aagtgtctgg attacaggcg tgaatcactg cgcctggctt
2461 cctcttccct ttgagaaata tctctttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgttaca agtgtctggt cctttctgag ggaggctggt gccgctctgc
2581 aggggtatttg aacctgtgga attggaggag gccatttcac tcctgaacc cagcctgaca
2641 aatcacagtg agaattgtca ccttataggc ttgctgtggg gctcagggtg aaagtgtggg
2701 gagtgcact gcctaggcat ccagctcagt gtcattccagg gcctgtgtcc ctcccgaacc
2761 caggggtcaac ctgcttgcca caggcactag aaggacgaat ctgcttactg cccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctgttc ctgtccttgc cctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

```

```

//
LOCUS       HSU83239       932 bp       mRNA       PRI       02-MAY-1997
DEFINITION  Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION   U83239
NID         g2062424
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 932)
AUTHORS     Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE       Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
lymphocytes
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 932)
AUTHORS     Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE       Direct Submission
JOURNAL     Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620
            University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES    Location/Qualifiers
            source
                1..932
                /organism="Homo sapiens"
                /note="Amgen EST program"
                /db_xref="taxon:9606"
            CDS
                15..296
                /codon_start=1
                /product="CC chemokine STCP-1"
                /db_xref="PID:g2062425"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```


LPLRVVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQ"
 BASE COUNT 166 a 330 c 201 g 235 t
 ORIGIN
 1 atacaggaca gagcatggct cgcctacaga ctgcactcct ggttgctctc gtcctccttg
 61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
 121 gctgccgtga ttacgtccgt taccgtctgc ccttcgcgct ggtgaaacac ttctactgga
 181 cctcagactc ctgcccagg cctggcgctg tggttgtaac cttcagggat aaggagatct
 241 gtgccgatcc cagagtggcc tgggtgaaga tgattctcaa taagctgagc caatgaagag
 301 cctactctga tgaccgtggc cttggctcct ccaggaaggc tcaggagccc tacctccctg
 361 ccattatagc tgctccccc cagaagcctg tgccaactct ctgcattccc tgatctccat
 421 ccctgtggct gtcacccttg gtcacctccg tgctgtcact gccatctccc cctgacccc
 481 tctaaccat cctctgcctc cctccctgca gtcagagggt cctgttccca tcagcgattc
 541 ccctgcttaa acccttccat gactccccc tgccctaagc tgaggtcagt ctcccaagcc
 601 tggcatgtgg ccctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
 661 atgaatgttg ggttctagct ccctgttctc caaaccata ctacacatcc cacttctggg
 721 tctttgcctg ggtgttgct gacactcaga aagtcccacc acctgcacat gtgtagcccc
 781 accagccctc caaggcattg ctgcccagg cagctggtaa ttccatttca tgtattagat
 841 gtcccctggc cctctgtccc ctcttaataa ccctagtcac agtctccgca gattcttggg
 901 atttgggggt tttctcccc acctctccac ta

//
 LOCUS HSMCP1 725 bp RNA PRI 03-APR-1995
 DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
 ACCESSION X14768
 NID g34513
 KEYWORDS monocyte chemoattractant protein 1.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 725)
 AUTHORS Yoshimura, T., Yuhki, N., Moore, S.K., Appella, E., Lerman, M.I. and
 Leonard, E.J.

TITLE Human monocyte chemoattractant protein-1 (MCP-1). Full-length
 cDNA
 cloning, expression in mitogen-stimulated blood mononuclear
 leukocytes, and sequence similarity to mouse competence gene JE
 JOURNAL FEBS Lett. 244 (2), 487-493 (1989)
 MEDLINE 89153605
 COMMENT ZAPII.

FEATURES
 source Location/Qualifiers
 1..725
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="glioma cells"
 /cell_line="U105MG"
 /clone_lib="lambda"
 sig_peptide 54..122
 /note="signal peptide (AA -23 to -1)"
 CDS 54..353
 /codon_start=1
 /product="monocyte chemoattractant preprotein"
 /db_xref="PID:g34514"
 /db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCYNFTNRKIS

VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT"
 mat_peptide 123..350
 /note="MCP-1 (AA 1 - 76)"
 misc_feature 162..170
 /note="pot. N-linked glycosylation site"
 misc_feature 707..712
 /note="pot. polyA signal"
 polyA_site 725
 /note="polyA site"

BASE COUNT 208 a 171 c 126 g 220 t
 ORIGIN

1 ctaaccaga aacatccaat tctcaaactg aagctcgac tctcgctcc agcatgaaag
 61 tctctgccc ctttctgtgc ctgctgctca tagcagccac cttcattccc caagggtctg
 121 ctcagccaga tgcaatcaat gccccagtca cctgctgtta taacttcacc aataggaaga
 181 tctcagtga gaggtctcg agctatagaa gaatcaccag cagcaagtggt cccaaagaag

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt attttccctt agctttccctt agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaatgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttta
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt tttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
721 tgtac

```

```

//
LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        gl905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
AUTHORS    Van Coillie, E., Fiten, P., Nomiyama, H., Sakaki, Y., Miura, R.,
            Yoshie, O., Van Damme, J. and Opdenakker, G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
JOURNAL    Genomics 40 (2), 323-331 (1997)
MEDLINE    97237052
REFERENCE  2 (bases 1 to 2991)
AUTHORS    Opdenakker, G.M.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,

```

```

BELGIUM
FEATURES             Location/Qualifiers
    source            1..2991
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
    repeat_region     209..219
                     /map="ql1.2"
                     /note="DR-A"
    repeat_region     240..248
                     /rpt_type=DIRECT
                     /note="DR-B"
    CAAT_signal       296..300
    repeat_region     310..318
                     /rpt_type=DIRECT
                     /note="IR-A"
    repeat_region     406..415
                     /rpt_type=INVERTED
                     /note="DR-B"
    repeat_region     407..416
                     /rpt_type=DIRECT
                     /note="IR-B"
    repeat_region     425..435
                     /rpt_type=INVERTED
                     /note="DR-A"
    repeat_region     429..437
                     /rpt_type=DIRECT
                     /note="IR-B"
    repeat_region     455..465
                     /rpt_type=INVERTED
                     /note="IR-C"
    TATA_signal       467..472
    repeat_region     492..502
                     /rpt_type=INVERTED
                     /note="IR-C"
    repeat_region     492..500
                     /rpt_type=INVERTED
                     /note="IR-A"

```

```

/rpt_type=INVERTED
exon      534..639
          /gene="MCP-2 (SCYA10)"
          /number=1
gene      534..1969
          /gene="MCP-2 (SCYA10)"
CDS       join(534..639,1331..1448,1864..1969)
          /gene="MCP-2 (SCYA10)"
          /codon_start=1
          /product="monocyte chemotactic protein-2"
          /db_xref="PID:e279930"
          /db_xref="PID:g1905801"

/translation="MLKLTPSPKMKVSAALLCLLLMAATFSPQGLAQPDSVSIPITC
CFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTQRGKEVCADPKERWVRDSMKHLDQ
IFQNLKP"
intron    640..1330
          /gene="MCP-2 (SCYA10)"
          /number=1
exon      1331..1448
          /gene="MCP-2 (SCYA10)"
          /number=2
intron    1449..1863
          /gene="MCP-2 (SCYA10)"
          /number=2
exon      1864..1969
          /gene="MCP-2 (SCYA10)"
          /number=3

BASE COUNT      799 a      709 c      632 g      851 t
ORIGIN
1 agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61 tgggggttcta aaggagcttg cctggcttag aactgcaagt gactctagtg tgatggagag
121 caccagcaaa gccttagggc ccatccctgg cctcctgtta cccacagagg ggtaagcctt
181 ggctctcttc cactatgacg tcagcttcca ttcttccttt cttatagaca attttccatt
241 tcaaggaaat cagagccctt aatagtccag tgaggctcact ttgctgagca caatcccata
301 cccttcagcc tctgtctcac agagcctaag caaaagatag aaactcacaa cttccttggt
361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggtctt
421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481 agagccaccg aggagcagag aggttgagaa caaccagaa accttcacct ctctgctga
541 agctcacacc ctggccctcc aagatgaagg tttctgcagc gcttctgtgc ctgtgctca
601 tggcagccac ttccagccct cagggacttg ctcagccagg taagacctct ccttttttaa
661 ggggagacca aaagaggaaat taagaagagc cattatgtca cagctcatta ggaacaaaac
721 cagaactaaa ggctcaggtc actgaggctg gttcccttga tcttccctga cccagtttt
781 gggaggagac agtggagccg ctacagcaac aacctcccca ttgtttgggg aaataatcca
841 gaacgaagaa ctgttttcta ctgtgggtgt aaaggacatt tcaggccgta ttggagaggg
901 agaaactatt gcctgaagct tcaaattttg gttatgggtc agtgtacctt ccagaacagt
961 ggctgtgttaa agaggatgag gaccagagg aatctcagcg tatggcatag cgttaactcta
1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgtcag
1081 aagttttggg ttagtagaca aggactagct tgttactcaa aatgtttcca aaccagtgca
1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
1201 gggatctgga ctaagacact gaacttgga tggtgacttc ttggtcttct ctttcttctt
1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
1381 attcctatcc agaggctgga gagctacaca agaatcacca acatccaatg tcccaaggaa
1441 gctgtgatgt gagtggacag tgccctggc acattcaa aagttctgat ggacaacata
1501 gagaagtcaa gattcatgtc catatgagtc ggatgcata aacttctatc caaaggggcc
1561 ctctacccca tagagaaact cagtcctgta gaaggagtcc ataatgtctc taggatcccc
1621 ttctaggggc ttgggtgaaac taaccacaata tctgtagcca ggaccttga gggtttcacc
1681 tggacagcaa gagcagagct tccttctgga gcttcttctt cccactcttc cctccctcc
1741 tctccccggg ccgggtctct cacctaagga ccaagggctg atcagtccta gggaccaaat
1801 gcccacagtc ctgtgcagga cttcaaaagt cttccatcta attgtccctt cttccctcca
1861 cagcttcaag acccaacggg gcaaggaggt ctgtgctgac cccaaggaga gatgggtcag
1921 ggattccatg aagcatctgg accaaatatt tcaaatctgt aagccatgag cttcatata
1981 tggactgaga gtcagagctt gaagaaaagc ttattttatt tccccaaact cccccagggt
2041 cagtgtgaca ttattttatt ataacatcca caaagagatt atttttaaat aatttaaacg
2101 ataataattc ttaaaaagta ttaattata ttaagttgt tgatgtttta actctatctg
2161 tcatacatcc tagtgaatgt aaaaagcaaa atcctgggtg tggtgttttt gtttttggtt
2221 tcctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctcct acctgtctgt
2281 agtgtgtggg ggtcctccca tggatcatca aggtgaaaca ctttggtatt ctttggaat
2341 cagtgtcctt gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tgggaattttg aaaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gagtgaagtt tgggcatcat
2521 ggggtgacagt ttggggcatgg acggggccatt tttcaagaat gtctcttggc tacgctggac
2581 tcaaccaagg ttctcagaga acttgggtggg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccctgattcg ctagcctctc ttgtttctct tgtttatata
2701 ttatccagcc taaggtatatt tgttatagct gcccaaaaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgacccg ccatattgag ccatacatac cgagcttatt atttttccag
2941 cttattggga aaacacgtct aaggcaaca aatttattgt actgttgaac c
//LOCUS      HSY16645      1368 bp      mRNA      PRI      25-SEP-1998
DEFINITION   Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION    Y16645
NID          g2916795
KEYWORDS     MCP-2 gene; monocyte chemotactic protein 2.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
              Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1368)
AUTHORS      Van Coillie,E.
TITLE        Functional comparison of two human monocyte chemotactic
protein-2
              isoforms, role of the amino-terminal pyroglutamic acid and
              processing by CD26/dipeptidyl peptidase IV
JOURNAL      Biochemistry 37, 12672-12680 (1998)
REFERENCE    2 (bases 1 to 1368)
AUTHORS      Van Coillie,E.
TITLE        Direct Submission
JOURNAL      Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical
              Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT      Related sequences: X99886, Y10802.
FEATURES
    source          Location/Qualifiers
                    1..1368
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /chromosome="17"
                    /tissue_type="testis"
                    /clone_lib="Clontech"
                    /clone="HL1142q"
                    /map="ql1.2"
    gene            473..772
                    /gene="MCP-2"
    sig_peptide     473..541
                    /gene="MCP-2"
    CDS             473..772
                    /gene="MCP-2"
                    /codon_start=1
                    /product="monocyte chemotactic protein-2"
                    /db_xref="PID:e1253690"
                    /db_xref="PID:g2916796"

/translation="MKVSAALLCLLLMAATFSPQGLAQPDSVSIPITCCFNVINRKIP
IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
    mat_peptide     542..769
                    /gene="MCP-2"
    variation       677
                    /gene="MCP-2"
                    /note="polymorphism, Lys -> Gln"
                    /replace="c"
BASE COUNT      457 a      292 c      243 g      376 t
ORIGIN
    1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
    61 tcctgttacc cacagagggg taggcccttg gctctcttcc actatgacgt cagcttccat
    121 tcttcctttc ttatagacaa ttttccattt caaggaaatc agagccctta atagttcagt
    181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gagcctaagc
    241 aaaagataga aactcacaac ttccttgttt tgttatctgg aaattatccc aggatctggt
    301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgccc
    361 aggcctctctg ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaa

```

```

421 aaccagaaa cttcacctc tcattgtgaa gtcacaccc ttgcctcca agatgaaggt
481 ttctgcagcg cttctgtgcc tgctgtcat ggcagccact ttccagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
601 tcctatccag aggtgggaga gctacacaag aatcaccaac atccaatgct ccaaggaagc
661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gacccaagg agagatgggt
721 cagggattcc atgaagcatc tggaccaa atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcagag cttgaagaaa agcttattta ttttcccccag cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtatttaatt atatttaagt tgttgatgtt ttaactctat
961 ctgtcataca tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgttttg
1021 ttttcctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgtc
1081 tgtagtgttg tggggctctc ccatggatca tcaagggtgaa acactttggt attctttggc
1141 aatcagtgtc cctgtaagtc aaatgtgtgc tttgtactgc tgttgttgaa attgatgtta
1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaata tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

```

//LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION   H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION    X72308 S57464
NID          g313707
KEYWORDS     monocyte chemotactic protein 3.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE        Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of           the cDNA and comparison with other chemokines
              Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
              MEDLINE 93213290
REFERENCE    2 (bases 1 to 1085)
AUTHORS      Opdenakker,G.M.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University   of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE    3 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
              Speleman,F., Laureys,G. and Van Damme,J.
TITLE        The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
              assignment to the C-C chemokine gene cluster on chromosome
              17q11.2-q12
              JOURNAL Genomics 21 (2), 403-408 (1994)
              MEDLINE 94375065
FEATURES     Location/Qualifiers
              source      1..1085
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
              gene        299..810
                           /gene="MCP-3"
              CDS          299..628
                           /gene="MCP-3"
                           /codon_start=1
                           /product="monocyte chemotactic protein-3"
                           /db_xref="PID:g313708"
                           /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAAALCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPQRLESYRRTTSSHC PREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
              KTQTPKL"
              sig_peptide 299..397
                           /gene="MCP-3"
              mat_peptide 398..625
                           /gene="MCP-3"
                           /product="monocyte chemotactic protein-3"
              polyA_signal 806..810
                           /gene="MCP-3"
BASE COUNT   314 a      214 c      229 g      328 t

```

ORIGIN

```

1  gggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctggt
121 tcccgtgggg gtgtgggctag gctaagcggt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccaggg gcttgcctcag ccagtggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtgggtctg agattatatt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841 ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctcctc
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtcaaaa gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttataataat acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

//

```

LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
            ORGANISM
              Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of          the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source          1..1085
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
            gene            299..810
                               /gene="MCP-3"
            CDS              299..628
                               /gene="MCP-3"
                               /codon_start=1
                               /product="monocyte chemotactic protein-3"
                               /db_xref="PID:g313707"
                               /db_xref="SWISS-PROT:P80098"

/translation="MWKPMSPSPNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPRÉAVIFKTKLDKEICADPTQKWWQDFMKHLDK
KTQTPKL"
            sig_peptide     299..397
                               /gene="MCP-3"
            mat_peptide     398..625

```

```

                /gene="MCP-3"
polyA_signal    /product="monocyte chemotactic protein-3"
                806..810
                /gene="MCP-3"
BASE COUNT      314 a    214 c    229 g    328 t
ORIGIN
1  ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61 ctggggcttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctggt
121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtgggtg tttagagggt gaactcactg gaatggggat gcttgcattg
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgcctag ccagtgggga ttaatacttc
421 aactacctgc tgcacagat ttatcaataa gaaaatccct aagcagaggtc tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgtgaccc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatttt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781 gatttttaaaa gttattaata ttttaattta atcttccatg gattttgggt ggttttgaac
841 ataaagcctt ggatgtatat gtcattctag tgcgtgaaaa actgtgggat gtcctccctc
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcata gatttgcctt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtatacaaaa aaaaaaaaaa
1081 aaaaaa

//LOCUS      HSU46767      825 bp      mRNA      PRI      16-DEC-1996
DEFINITION   Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
complete cds.
ACCESSION    U46767
NID          gl732122
KEYWORDS
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A., Combadiere, C.C., Rothenberg, M.E.,
Sarafi, M.N., Lavigne, F., Hamid, Q., Murphy, P. and Luster, A.D.
TITLE        Human monocyte chemoattractant Protein (MCP)-4: A novel CC
              chemokine with activities on monocytes, eosinophils, and
basophils
              induced in allergic and non-allergic inflammation that signals
              through the CC chemokine receptors CCR-2 and 3
JOURNAL      J. Immunol. 158 (1996) In press
REFERENCE    2 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A. and Luster, A.D.
TITLE        Direct Submission
JOURNAL      Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
              Disease Unit, Massachusetts General Hospital, 149 13th St.,
              Charlestown, MA 02129, USA
FEATURES
source       Location/Qualifiers
              1..825
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /tissue_type="heart"
              /clone_lib="EG3.16"
sig_peptide  34..102
              /gene="MCP-4"
CDS          34..330
              /gene="MCP-4"
              /note="small cytokine; intercrine/chemokine; C-C
subfamily    signature; chemoattractant for monocytes, eosinophils"
              /codon_start=1
              /product="monocyte chemoattractant protein-4
precursor"    /db_xref="PID:gl732123"

/translation="MKVSAVLLCLLLMTAAFPNQGLAQPDALNVPSTCCFTFSSKKIS

```

LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT"

gene 34..330
/gene="MCP-4"
mat_peptide 103..327
/gene="MCP-4"

BASE COUNT 221 a 175 c 185 g 244 t
ORIGIN

```

1 acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gcttctgtgc
61 ctgctgctca tgacagcagc tttcaacccc cagggacttg ctcagccaga tgcactcaac
121 gtcccatcta cttgtgtgct cacatttagc agtaagaaga tctccttgca gaggtgtaag
181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcattctcag aaccaaactg
241 ggcaaggaga tctgtgtgta cccaaaggag aagtgggtcc agaattatat gaaacacctg
301 ggccggaaaag ctcacacccct gaagacttga actctgtctac ccctactgaa atcaagctgg
361 agtacgtgaa atgacttttc cattctcttc tggcctcctc tttctatgctt tgggaatactt
421 ctaccataat tttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
481 agtaatatgt gctattattt gacttgttgc tgggtttggag tttatttgag tattgctgat
541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagccccc ttcccttcca
601 ctatgagctg ctggcagtggt gttgtattcg gttcccaggg gttgagagca tgcctgtggg
661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
781 tgcagaaaaa acattttatt taaaatcttc taaaaaaaaa aaaaaa

```

//LOCUS HSAMAC1 803 bp RNA PRI 10-AUG-1997
DEFINITION Homo sapiens mRNA for alternative activated macrophage specific
CC

chemokine 1.
ACCESSION Y13710
NID g2326515
KEYWORDS AMAC-1 gene; CC-chemokine 1.
SOURCE human. ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

REFERENCE 1 (bases 1 to 803)
AUTHORS Politz,O.
TITLE Direct Submission
JOURNAL Submitted (10-JUN-1997) Politz O., Dermatology, Free University
Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
Berlin

GERMANY
REFERENCE 2 (bases 1 to 803)
AUTHORS Kodelja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
Goerdts,S.
TITLE Cloning of alternative activated macrophage associated CC
chemokine

1 (AMAC-1)
JOURNAL Unpublished

FEATURES Location/Qualifiers
source 1..803
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="macrophage"
sig_peptide 71..133
/gene="amac-1"
CDS 71..340
/gene="amac-1"
/note="macrophage specific"
/codon_start=1
/product="CC-chemokine 1"
/db_xref="PID:e321838"
/db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSAQVGTNKLCCLVYTSWQIPQKFI
VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLN"

gene 71..340
/gene="amac-1"
mat_peptide 134..337
/gene="amac-1"

BASE COUNT 214 a 213 c 160 g 216 t
ORIGIN


```

1 cccgcacgag aggagttgtg agtttccaag ccccgactca ctctgaccac ttctctgcct
61 gcccgacatc atgaagggcc ttgcagctgc cctccttgtc ctgctctgca ccatggccct
121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgctctgtct atacctcctg
181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccagct gcccacagcc
241 aggtgtcatc ctcctaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gcccgatgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg
421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgccagcca cattaactaa
481 ctttaatctt agtttatgca tcataattca ttttgaatt gatttctatt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttccctt
601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
661 cagacattgt gccatatgta tcaaatagaca aatctttatt gaatggtttt gctcagcacc
721 accttttaat atattggcag tacttattat ataaaaggta aaccagcatt ctcactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

```

```

//
LOCUS      HUMLD78A      3176 bp      DNA              PRI      17-JAN-1992
DEFINITION Human LD78 alpha gene.
ACCESSION  D90144
NID        g219905
KEYWORDS   LD78; LD78 alpha; cytokine; inducible gene family; secreted
           peptide.
SOURCE     Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;

```

```

REFERENCE  1 (bases 1 to 3176)
AUTHORS    Nakao,M., Nomiya,H. and Shimada,K.
TITLE      Structures of human genes coding for cytokine LD78 and their
           expression
JOURNAL     Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE     90287155
COMMENT     These data kindly submitted in computer readable form by:
Hisayuki

```

```

Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

```

```

FEATURES             Location/Qualifiers
     source            1..3176
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
     TATA_signal       1041..1045
     exon              1069..1227
                       /number=1
     prim_transcript   1069..2957
                       /note="LD78 alpha mRNA and introns"
     sig_peptide        1155..1220
                       /note="LD78 alpha signal peptide"
     CDS                join(1155..1227,1916..2030,2451..2541)
                       /codon_start=1
                       /product="LD78 alpha precursor"
                       /db_xref="PID:d1014875"
                       /db_xref="PID:g219906"

```

```

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSTSRQIPQ
NFIADYFETSSQCSKPGVIFLTRSRQVCADPSEEWVQKYVSDLELSA"
     mat_peptide       1218..1227,1916..2030,2451..2538)
                       /partial
                       /note="LD78 alpha mature peptide"
     intron            1228..1915
     exon              1916..2030
                       /partial
                       /number=2
     intron            2031..2450
     exon              2451..2957
                       /number=3

```

```

BASE COUNT      833 a    741 c    752 g    850 t
ORIGIN
1  acccagggac ctatcacaca aatataagaa ctattcattc ttaaagggcat gtattttccaa
61  gcctttgtat ttttttccat gcttaggggt ggcaaggaat atatatatat ttgtacaaat
121 atatatgtgt atagtacaa atacatgtat atatatgaca aatatatata tatatttgta
181 caattcttca gactttgtag aatttgtata atgtcgtatc ttgctttttt taaccactga
241 tgttataagc atatttatgc cacttcattc attttagaga cttaataata aatgatctag
301 tggataaatt atcattccct gatggagaaa aatttagcct tgtttatttt agagttataa
361 acgatgctgg gtcaggatgc tttatgtttg aagatggctc catatttggg ttgtttccac
421 agaactcttt cctagaaatg ctttttctag gttaatggct acagatattt ctaggcacct
481 gacatattga caccacctc taaagtattt ttatgatcca caactagcgt ttaacacagc
541 gccctagtca ctacatgact aataaataga caaatgactg aaacatgacc tcatgctttc
601 tattcctcca gctttcattc agttcctttg ctctgggagg aggaagggtt gtgcagccct
661 ccacagcatc agcccatcaa ccttatccct gtggttatag cagctgagga agcagaattg
721 cagctctgtg ggaaggaatg gggctggaga gttcatgcac agaccatttc ttatgagaag
781 ggactgacta agaatagcct tgggttgaca tataccctc ttcacactca caggagaaac
841 catttcccta tgaactata acaagtcatg agttgagagc tgagagtttag agaatagtct
901 aaagatgcta ttcttgata tcctggagccc ctgtgtgtcac cagggacctt gagttgtgca
961 acttagcatg acagcatcac tacgttataa aatttccctc ctcaccccca gattccattt
1021 ccccatccgc cagggctgcc tataaaggag agagctgggt tcagacttca gaaggacacg
1081 ggcagcagac agtggtcagt ccttctttgg ctctgctgac actcgagccc acattccgtc
1141 acctgctcag aatcatgcag gtctccactg ctgcccttgc tgtcctcttc tgcacctagg
1201 ctctctgcaa ccagttctct gcatacagtg agtctgagtt tcgttgtggg tatccacct
1261 ctctggccat ggttagacca catcaatctt ttcttgtggc ctaaaagccc ccaagagaaa
1321 agagaacttc ttaaagggtc gccaaacatc ttggtctttc tctttaagac tttattttt
1381 atctctagaa ggggtcttag ccccttagtc tccaggtatg agaacttagg caggggcagg
1441 ggagttacag tcccttttac agatagaaaa acaggggttc aaacgaatca gttagcaaga
1501 ggcagaatcc agggctgctt acttcccagt ggggtatggt gttcactctc cagctcactc
1561 taggtctccc aggagctctg tcccttggat gtcttatgag agatgtccaa ggcttctctt
1621 ggggtggggg atgacttctt gaaccagaca aaattccctg aagagaactg agataagaga
1681 acagtccgtt caggatatct gatcacacag agaaacagag aaccactat gaagagtcaa
1741 ggagaaagaa ggatacagac agaaacaaag agacatttct cagcaaaaat gcccaaatgc
1801 cttccagtca ctgtgtctga gcaagcctgc cttcctcaac tgctcgggga tcagaagctg
1861 cctggccttt tcttctgagc tgtgactcgg gctcattctc tctcttctc cacagttgct
1921 gctgacacgc cgaccgctg ctgcttcagc tacacctccc ggcagatttc acagaatttc
1981 atagctgact actttgagac gagcagccag tgctccaagc ccggtgtcat gtaagtcca
2041 gtcttctgct tcacctctat ggaggtaggg agggtcaggg ttggggcaga gacaggccag
2101 aaggctatcc tggaaaggcc cagccttcag gagcctatcg gggatacagc acgcagggtc
2161 ccgaggtgtg acctgacttg gagctggagt gaggcatgtg ttacagagtc aggaagggtc
2221 gccccagccc agaggaaagg gacaggaaga agggagcagc gggacactct gagggccacc
2281 cctactgagt cactgagaga agctctctag acagagatag gcagggggcc cctgaagag
2341 gagcaagccc tgagctgccc aggacagaga gcagaatggt ggggccatgg ttgggccagg
2401 attccctgct tggattcccc agtgcttaac tcttctcccc ttctccacag cttcctaacc
2461 aagcgaagcc ggcaggctct tgctgacccc agtgaggagt ggggtcagaa atagtgcagc
2521 gacctggagc tgagtgcctg aggggtccag aagcttccag gccacgcgac ctcggtgggc
2581 ccagtgggga ggagcaggag cctgagcctt gggaacatgc gtgtgacctc cacagctacc
2641 tcttctatgg actggttgtt gccaaacagc cacactgtgg gactcttctt aacttaattt
2701 ttaatttatt tatactattt agtttttgta atttattttc gatttcacag tgtgtttgtg
2761 attgtttgct ctgagagttc cctgttcccc tcccccttcc ctacaccgc gtctgtgtgac
2821 aaccgagtgg ctgtcatcag cctgtgtagg cagtcatggc accaaagcca ccagactgac
2881 aaatgtgtat cggatgcttt tgttcagggc tgtgatcggc ctggggaaat aataaagatg
2941 ctctttttaa aggtaaacca gtattgagtt tggttttggt tttctggcaa atcaaaatca
3001 ctggttaaga ggaatcatag gcaaagatta ggaagagggt aaatggaggg aaattgggag
3061 agatggggag ggctaccaca gagtatatcca ctttacaacg gagacacagt tctggaacat
3121 tgaaactacg aatatgttat aactcaaadc ataacatgca tgctctagga gaattc

```

```

//
LOCUS      AF043339      225 bp      mRNA                      PRI      23-FEB-1998
DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
mRNA,
partial cds.
ACCESSION  AF043339
NID        g2905627
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Jang, J.S. and Kim, B.E.
TITLE      Direct Submission
JOURNAL     Submitted (15-JAN-1998) Protein Engineering, General Institute

```

of Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong, Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
reverse primer (5'-cttctggaccctcaggcact-3').

FEATURES Location/Qualifiers

source 1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"

gene <1..225
/gene="MIP1a"

primer_bind <1..19
/gene="MIP1a"

cycles; /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30

CDS DeltaCycler II from Ericomp"
<1..213
/gene="MIP1a"
/function="CC chemokine"
/function="proinflammatory cytokine involved in inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSYTSRQIPQNFADYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"

primer_bind complement(205..225)
/gene="MIP1a"

BASE COUNT 50 a 68 c 62 g 45 t

ORIGIN
1 gcacacattg ctgctgacac gccgaccgcc tctgtgttca gctacacctc ccggcagatt
61 ccacagaatt tcataagctga ctactttgag acgagcagcc agtgctccaa gcccggtgtc
121 atcttcctaa ccaagcgaag ccggcagggtc tgtgtgtgacc ccagtgtgagga gtgggtccag
181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag

//

LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992

DEFINITION Human LD78 beta gene.

ACCESSION D90145

NID g219907

KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted peptide.

SOURCE Human placenta DNA, clone Lm LD-1.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;

REFERENCE 1 (bases 1 to 3112)

AUTHORS Nakao,M., Nomiya,H. and Shimada,K.

TITLE Structures of human genes coding for cytokine LD78 and their expression

JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)

MEDLINE 90287155

COMMENT These data kindly submitted in computer readable form by: Hisayuki Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES Location/Qualifiers

source 1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"

repeat_unit 498..797
/note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS              join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
              QNFIADYFETSSQCSKPSVIFLTRGRQVCADPSEEWQKYVSDLELSA"
sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide       join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron           1268..1952
exon             1953..2067
                  /number=2
intron           2068..2487
exon             2488..2955
                  /number=3
BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
1   ttagagactt aataataaag gatcttgttg ataatttatt attccctgat agagaaaaat
61  ttagctttgc ttattttaga gttataaatg atgctgggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctaggtt
181 aatggctaca catattttta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa ctagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tcctttcctc
361 tgggaggact ggggggttgc tagccctcca cagcatcagc ccattgacct tatccttggt
421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagaggt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcac tttgttgccc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc tccacctcc tgggttcaag
601 cgattctcct gccctcagcc tcccgagtag ctgggattac aggcattgtc caccacgcct
661 gactactttt gtatttttag tagagatgga gtttctcttt ctgtgtcagg ttggtctcaa
721 actcctgacc tcaggtgatc cgcagcctcg gcctcccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctgggtgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacacccct cttcacactc acaggagaaa ccccatgaag ctagaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatatcctg
961 agccccgtg gtcaccaggg accctgagtt gtgcaacact cagcatgaca gcatcactac
1021 acttaaaaat ttccctcttc acccccagat tccatttccc catccgccag ggctgcctat
1081 aaagaggaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtccc
1141 ttcttggtct tgctgacact cgagcccaca ttccatcacc tgctcccaat catgcaggtc
1201 tccactgctg cccttgccgt cctcctctgc accatggctc tctgcaacca ggtcctctct
1261 gcaccacgtg agtccatggt gttgtgtgtg gtatcaccac tctctggcca tgggttagacc
1321 acatcagttt ttttttgctg cctgagagcc ccgaagagaa aagaaggag ttcttaaaag
1381 gctgccaac accttggtct ttttcttcac aacttttatt tttatctcta gaaggggtct
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtccctt
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggct
1561 gcttacttcc cagtgggtgc tgtgtgtcac tctccagctc accctagggt tcccaggagc
1621 cctgtccctt ggaagtctta tgagagatgt ccagggtctt tcttgggctg gggtagact
1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaac agtccattca ggtatctgga
1741 tcacatagag aaacagagaa ccactatga agagtcaagg ggaaagagga atatagacag
1801 aaacaaagag acatttctct gcaaaaaccc ccaaatgcct tgcagtcact tggctctgagc
1861 aagcctgccc tctcaacca ctcagggtac agaagctgcc tggccttttc tctgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgtgtgt gacacgccga ccgctgctg
1981 ctccagctac acctcccgac agattccaca gaatttcata gctgactact ctgagacgag
2041 cagccagtgc tccaagccca gtgtcatgta agtgccagtc ttcctgtcca ccttagggga
2101 ggtagggagt gtcagggttg gggcagaaac aggccagaag gccatctgtg aaaggcccag
2161 ccttcaggag cctatcggtg atacaggagc cagggcactg aggtgtgacc tgacttgggg
2221 ctggagtgtg gtgggtgtta cagagtcagg aagggtgtgc ccaggccaga ggaagggaac
2281 aggaagaagg aggcagcagg acactctgag ggcccccttg cctggaagtca ctgagagaag
2341 ctctctagac ggagataggc agggggcccc tgagagagga gcaggccttg agctgccag
2401 gacagagagc aggatgtcag gccatggttg gccaggatt ccccggtgtg attccccagt
2461 gcttaactct tctcctctc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```

```

2521 tgacccagct gaggagtggt tccagaaata cgtcagtgac ctggagctga gtgcctgagg
2581 ggtccagaag cttcaggagg cagcgacctc agtgggcccc gtggggagga gcaggagcct
2641 gagccttggt aacatgcgtg tgacctctac agctacctct tctatggact ggttattgcc
2701 aaacagccac actgtggggac tcttcttaac ttaaatttta atttatttat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gtttctgatt gtttgcctct agagttcccc
2821 ctgtcccctc caccttcctt cacagtgtgt ctggtgacga ccgagtggct gtcacgggcc
2881 tgtgtaggca gtcattggac caaagccacc agactgacaa atgtgtatca gatgcttttg
2941 ttcaggggctg tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaacagct
3001 attgagtttg gttttgtttt tctggcaaat caaaatcact agttaagagg aatcataggg
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

//
LOCUS      HUMACT2A      696 bp      mRNA      PRI      30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION  J04130
NID        g178017
KEYWORDS   act2 gene; immune activation gene.
SOURCE     Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 696)
AUTHORS    Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE      Identification, cloning, and characterization of an immune
            activation gene
JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE    89071764
COMMENT     Draft entry and computer-readable sequence [1] kindly submitted
            by
            W.Leonard, 09-JAN-1989.
FEATURES   Location/Qualifiers
            source          1..696
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /map="Unassigned"
            mRNA            <1..696
                        /note="act-2 mRNA"
            sig_peptide     109..177
                        /gene="LAG2"
                        /note="act-2 protein signal peptide"
            gene            109..387
                        /gene="LAG2"
            CDS             109..387
                        /gene="LAG2"
                        /note="act-2 protein precursor"
                        /codon_start=1
                        /db_xref="GDB:G00-127-452"
                        /db_xref="PID:g178018"

/translation="MKLCVTVLSLLMLVAAPFCSPALSAPMGSDPPTACCFSTYARKLP
            RNFVVDYYETSSLCSQPAVVFTKRSKQVCADPSESWSVQEVYVDLELN"
            mat_peptide     178..384
                        /gene="LAG2"
                        /note="act-2 protein"
BASE COUNT      157 a      203 c      139 g      197 t
ORIGIN          Unreported.
1  ttcccccccc ccccccccc ccccgcccca gcacaggaca cagctgggtt ctgaagcttc
61 tgagtcttgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
181 ccaatgggct cagaccctcc caccgcctgc tgcttttctt acaccgcgag gaagcttctt
241 cgcaactttg ttgtagatta ctatgagacc agcagcctct gctccagacc agctgtggta
301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt caggggaagg
421 cacctgagcc cggatgcttc tccatgagac acatctcctc catactcagg actcctctcc
481 gcagttcctg tcccttctct taatttaate ttttttatgt gccgtgttat tgtattaggt
541 gtcattttca ttatttatat tagtttagcc aaaggataag tgccttatgg ggatgggtcca
601 ctgtcactgt ttctctgctg ttgcaaatat atggataaca catttgatcc tgtgtgtttt
661 ccataataaa actttaaaat aaaatgcaga cagtta

//
LOCUS      AF031587      481 bp      mRNA      PRI      02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901
 California Ave, Palo Alto, CA 94304, USA
 FEATURES Location/Qualifiers
 source 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"

/translation="MKVSVAALSCMLMLVAVLGSAQFINDAETELMSKLPENPVVL

NSFHFAADCCTSYISQSIPLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"

BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN

```

1 atgaaggtct cctgtggtgc cctctcctgc ctcattgttg ttgctgtcct tggatcccag
61 gcccagttca taaatgatgc agagacagag ttaatgatgt .caaagcttcc actggaaaat
121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacia
181 agcatcccggt gttcactcat gaaaagtatt ttgaaacga gcagcgagtg ctccaagcca
241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaaccag .tggtccggga
301 gtccaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
361 gggcagccac ccacctccta cactcctgtg gagtttcttg gtctgaaata cttaaaaaat
421 atatatttg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttcaattttt
481 t
  
```

//

LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,

partial cds.

ACCESSION AF043340

NID g2905629

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 234)

AUTHORS Jang, J.S. and Kim, B.E.

TITLE Direct Submission

JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of

Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgccgaccctggccactgaactg-3')
 reverse primer (5'-ccttccttctggtcagttgga-3').

FEATURES Location/Qualifiers

source

1..234

/organism="Homo sapiens"

/db_xref="taxon:9606"

/cell_type="PHA-treated peripheral blood leukocyte"

```

gene          <1..234
              /gene="MIP2a"
primer_bind   <1..21
              /gene="MIP2a"
              /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
              DeltaCycler II from Ericomp"
CDS           <1..222
              /gene="MIP2a"
              /function="CXC chemokine"
              /function="proinflammatory cytokine involved in
inflammation"
              /note="8-10 kDa"
              /codon_start=1
              /product="macrophage inflammatory protein 2 alpha"
              /db_xref="PID:g2905630"

/translation="APLATELRQCQLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATL
              KNGQKACLNPA SP MVKKIIEKMLKNGKSN"
primer_bind   complement(214..234)
              /gene="MIP2a"
BASE COUNT    74 a      70 c      54 g      36 t
ORIGIN
    1 gcaccctgg ccactgaact gcgctgccag tgcttcgaga ccctgcaggg aattcacctc
   61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgcccc aaccgaagtc
  121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catggttaag
  181 aaatcatcgc aaaagatgct gaaaaatggc aaatccaact gaccagaagg aagg

//
LOCUS          HSU77035      764 bp      mRNA                      PRI      23-JAN-1997
DEFINITION     Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
                complete cds.
ACCESSION      U77035
NID            gl790924
KEYWORDS
SOURCE         human.
ORGANISM       Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 764)
AUTHORS        Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
                Zlotnik,A.
TITLE          Identification through bioinformatics of two new macrophage
                proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL        J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE        97166046
REFERENCE      2 (bases 1 to 764)
AUTHORS        Rossi,D.L. and Zlotnik,A.
TITLE          Direct Submission
JOURNAL        Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
                California Ave., Palo Alto, CA 94304, USA
FEATURES
    source      Location/Qualifiers
                1..764
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /cell_type="elutriated monocytes activated with
                LPS/IFN-GAMMA"
    gene        1..291
                /gene="MIP-3a"
    CDS         1..291
                /gene="MIP-3a"
                /note="chemokine"
                /codon_start=1
                /product="macrophage inflammatory protein 3 alpha"
                /db_xref="PID:gl790925"

/translation="MCCTKSLLLAALMSVLLHLGGESEAASNFDCLGYTDRI LHPK
              FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKVKNM"
BASE COUNT    235 a      121 c      146 g      260 t      2 others
ORIGIN
    1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgcgtgt actccacctc

```

```

61 tgcggcgaat cagaagcagc aagcaacttt gactgctgtc ttggatacac agaccgtatt
121 cttcatccta aatttattgt gggcttcaca cggcagctgg ccaatgaagg ctgtgacatc
181 aatgctatca tctttcacac aaagaaaaag ttgtctgtgt gcgcaaatcc aaaacagact
241 tgggtgaaat atattgtgcg tctctcagt aaaaaagtca agaactgtga aaaactgtgg
301 cttttctgga atggaattgg acatagccca agaacagaaa gaaccttgct ggggttgagg
361 gtttcacttg cacatcatgg agggtttagt gcttatctaa tttgtgcctc actggacttg
421 tccaattaat gaagttgatt catattgcat catagtttgc tttgtttaag catcacatta
481 aagttaaact gtattttatg ttattttatg ctgtagggtt tctgtgttta gctatttaac
541 actaattttc cataagctat tttggtttag tgcaagatat aaaattatat ttggggggga
601 ataagattat atggactttt ttgcaagcaa caagctattt tttaaaamma actatttaac
661 attcttttgt ttatattgtt ttgtctccta aattgttgta attgcattat aaaataagaa
721 aaatattaat aagacaaata ttgaaataa agaaacaaaa agtt

//
LOCUS      HSU77180      545 bp      mRNA                      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
complete cds.
ACCESSION  U77180
NID        g1791002
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL     J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE     97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="macrophages activated with LPS or IFNg"
                        /chromosome="9"
            gene            1..297
                        /gene="MIP-3beta"
            CDS             1..297
                        /gene="MIP-3beta"
                        /function="chemokine"
                        /codon_start=1
                        /product="macrophage inflammatory protein 3 beta"
                        /db_xref="PID:g1791003"

/translation="MALLLALSLVLWTSPAPTLSGTND AEDCCLSVTQKPIPGYIVR
NFHYLLIKDGRVPAVVFTTLRGRQLCAPDPQWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      125 a      160 c      153 g      107 t
ORIGIN
1 atggccctgc tactggccct cagcctgctg gttctctgga cttccccagc cccaactctg
61 agtggcacca atgatgctga agactgctgc ctgtctgtga cccagaaacc catccctggg
121 tacatcgatg ggaacttcca ctacctctc atcaaggatg gctgcagggt gcctgctgta
181 gtgttcacca cactgagggg cgcgcagctc tgtgcacccc cagaccgccc ctgggtagaa
241 cgcacatccc agagactgca gaggacctca gccaaagatga agcgcgcgag cagttaacct
301 atgaccgtg agagggagcc cggagtcgga gtcaagcatt gtgaattatt acctaacctg
361 gggaaaccgag gaccagaagg aaggaccagg cttccagctc ctctgcacca gacctgacca
421 gccaggacag ggcctggggt gtgtgtgagt gtgagtgatg gcgagagggt gagtgtggtc
481 tagagtaaag ctgctccacc cccagattgc aatgctacca ataaagccgc ctggtgttta
541 caact

//
LOCUS      HUMTCSM      1160 bp      mRNA                      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```


KEYWORDS Alu repeat; T-cell-specific protein.

SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA, clone 228.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1160)

AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J., Clayberger,C., Davis,M.M. and Krensky,A.M.

TITLE A human T cell-specific molecule is a member of a new gene family

JOURNAL J. Immunol. 141, 1018-1025 (1988)

MEDLINE 88285659

COMMENT Draft entry and computer-readable sequence for [1] kindly provided by A.M.Krensky, 24-OCT-1988.

FEATURES
source Location/Qualifiers
1..1160
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS 27..302
/note="T cell-specific protein precursor"
/codon_start=1
/db_xref="PID:g339421"

/translation="MKVSAARLAVILIATALCAPASASPYSSDTPCCFAYIARPLPR
sig_peptide 27..95
/note="T cell-specific protein signal peptide"
mat_peptide 96..299
/note="T cell-specific protein"
repeat_region 450..950
/note="Alu-related repeats"

BASE COUNT 298 a 332 c 295 g 235 t

ORIGIN 276 bp upstream of RsaI site.
1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
61 tcattgctac tgcctctcgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
121 cctgctgctt tgcctacatt gcccgccac tgcctcctgc ccacatcaag gagtatttct
181 acaccagtgg caagtgcctc aaccagcagc tcgtctttgt caccgaaag aaccgccaag
241 tgtgtgcaa cccagagaag aaatgggttc gggagtacat caactctttg gagatgagct
301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgctcttgc
361 cctagcttgg gaggtctccc ctactatcc taccacacc gctccttgaa gggccagat
421 tctgaccacg acgagcagca gttacaaaaa ccttccccag gctggacgtg gtggctcagc
481 ctgttaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagtctg
541 agacagcctg gccaacatga tgaacccca tgtgtactaa aaatacaaaa aattagccgg
601 gcgtggtagc gggcgctgt agtcccagct actcgggagg ctgaggcagg agaattggcgt
661 gaacccggga gcggagcttg cagtgcgccc agatcgcgcc actgcactcc agcctgggag
721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaataca aaaattagcc
781 gcgtgggtgg ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
841 gaacccagga ggtggaggct gcagtgcgct gagattgtgc cacttcactc cagcctgggt
901 gacaaagtga gactccgtca caacaacaac aacaaaaaagc ttcccaact aaagcctaga
961 agagcttctg aggcgtgct ttgtcaaaag gaagtctcta gggtctgagc tctggctttg
1021 ccttggcttt gcaagggctc tgtgacaagg aaggaagtca gcattgcctc agaggcaagg
1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
1141 gcaaacatga aaatcgggg

//

LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995

DEFINITION Human secreted protein (I-309) mRNA, complete cds.

ACCESSION M57502

NID g339728

KEYWORDS secreted protein.

SOURCE Human T-cell, cDNA to mRNA.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 520)

AUTHORS Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.

TITLE A novel polypeptide secreted by activated human T lymphocytes

JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522

FEATURES

source 1..520
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="T-cell"
/germline
/map="17"

mRNA <1..520
/gene="SCYA1"
/note="G00-118-872"

gene 1..520
/gene="SCYA1"

CDS 51..341
/gene="SCYA1"
/codon_start=1
/db_xref="GDB:G00-118-872"
/product="secreted protein I-309"
/db_xref="PID:g339729"

/translation="MQIITLALVCLLLAGMWPEDVDSKSMQVPPSRCCFSFAEQEIPL
RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPKSRK"

BASE COUNT 140 a 137 c 122 g 121 t
ORIGIN

1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca
61 tcaccacagc cctggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca
121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc
181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat
241 tcaagctgaa gagaggcaaa gaggcctgcg cttggacac agttggatgg gttcagaggg
301 acagaaaaat gctgaggcac tgcccgtcaa aaagaaaatg agcagatttc ttccattgt
361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct
421 tctgcctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttggtg
481 cactttaaac atttaaatta tacaatcatc aacccccaac

//

LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997

DEFINITION Human mRNA for EB11-ligand chemokine, complete cds.

ACCESSION AB000887

NID g2189952

KEYWORDS EB11-ligand chemokine; ELC.

SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.

REFERENCE 1 (bases 1 to 687)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyaama,H. and Yoshie,O.

TITLE Direct Submission

JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
Hisayuki Nomiyaama, Kumamoto University Medical School,

Department of Biochemistry; Honjo 2-2-1, Kumamoto. Kumamoto 860, Japan
(E-mail:nomiyaama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

REFERENCE 2 (sites)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyaama,H. and Yoshie,O.

TITLE Molecular cloning of a novel human CC chemokine EB11-ligand
chemokine that is a specific functional ligand for EB11, CCR7

JOURNAL J. Biol. Chem. 272 (21), 13803-13809 (1997)

MEDLINE 97298088

FEATURES

source 1..687
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="fetal"
/tissue_lib="lung"

gene 139..435
/gene="ELC"

```

CDS             139..435
                /gene="ELC"
                /note="CC chemokine"
                /codon_start=1
                /product="EBI1-ligand chemokine"
                /db_xref="PID:d1021215"
                /db_xref="PID:g2189953"

/translation="MALLLALLLVLTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGC RVPVAVFTTLRGRQLCAPDPQWVERIIQRLQRTSAKMKRSS"
mat_peptide     202..432
                /gene="ELC"
                /product="EBI1-ligand chemokine"
polyA_signal    657..662
BASE COUNT     154 a    223 c    173 g    137 t
ORIGIN
1 cattcccagc ctcacatcac tcacaccttg catttcaccc ctgcatecca gtcgccctgc
61 agcctcacac agatcctgca cacacccaga cagctggcgc tcacacattc accgttggcc
121 tgcctctgtt caccctccat ggccctgcta ctggccctca gctgtgctgt tctctggact
181 tccccagccc caactctgag tggcaccaat gatgctgaag actgctgcct gtctgtgacc
241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggatggc
301 tgcagggtgc ctgctgtagt gttcaccaca ctgagggggc gccagctctg tgcaccccca
361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccagggt tccagctcct
541 ctgcaccaga cctgaccagc caggacaggg cctgggggtg gtgtgagtg gtgtgtgagc
601 gagagggtga gtgtgttcag agtaaagctg ctccaccccc agattgcaat gctaccaata
661 aagccgcctg gtgtttacaa ctaattg

//
LOCUS           AB000221       760 bp    mRNA                PRI       31-JUL-1997
DEFINITION      Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION       AB000221
NID             g2289718
KEYWORDS        CC chemokine; PARC; pulmonary and activation-regulated
chemokine.
SOURCE          Homo sapiens lung cDNA to mRNA.
ORGANISM        Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
                Homo.
REFERENCE       1 (bases 1 to 760)
AUTHORS         Nomiya,H.
TITLE           Direct Submission
JOURNAL         Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
                Hisayuki Nomiya, Kumamoto University Medical School,
Department
                of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
                (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
                Fax:81-96-372-6140)
REFERENCE       2 (sites)
AUTHORS         Hieshima,K., Imai,T., Baba,M., Shoudai,K., Ishizuka,K.,
                Nakagawa,T., Tsuruta,J., Takeya,M., Sakaki,Y., Takatsuki,K.,
                Miura,R., Opdenakker,G., Damme,J., Yoshie,O. and Nomiya,H.
TITLE           A novel human CC chemokine PARC that is most homologous to
macrophage-inflammatory protein-1alpha/LD78alpha and
chemotactic
                for T lymphocytes, but not for monocytes
JOURNAL         J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE         97376836
FEATURES        Location/Qualifiers
                source          1..760
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="lung"
                gene            64..333
                        /gene="PARC"
                CDS             64..333
                        /gene="PARC"
                        /note="pulmonary and activation-regulated chemokine"

```

/codon_start=1
 /product="CC chemokine"
 /db_xref="PID:d1022520"
 /db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSAQVGTNKLCLVYTSWQIPQKFI
 VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

BASE COUNT 186 a 208 c 155 g 211 t
 ORIGIN

```

1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgccccagc
61 atcatgaagg gccttgcagc tgccttcctt gtctctgtct gcaccatggc cctctgctcc
121 tgtgcacaag ttggtaccaa caaagagctc tgctgcctcg tctatacctc ctggcagatt
181 ccacaaaagt tcatagttag ctattctgaa accagccccc agtgcccaa gccagggtgc
241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
301 aaatacatca gcgacctgaa gctgaatgcc tgaggggcct ggaagctgcg agggcccagt
361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccaccct
421 ggaggccacc tcttctaaga gtcccattcg ctatgccag ccacattaac taactttaat
481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
601 caactcttcg tacattcaat gcatggatca atcagtgtga ttagctttct cagcagacat
661 tgtgccatat gtatcaaatg acaaatcttt attgaatggt tttgctcagc accacctttt
721 aatatattgg cagtacttat tatataaaag gtaaaccagc

```

//

LOCUS D86955 799 bp mRNA PRI 06-MAR-1997
 DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
 ACCESSION D86955
 NID g1871138
 KEYWORDS CC chemokine LARC precursor.
 SOURCE Homo sapiens cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (sites)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyaama,H.
 TITLE Molecular cloning of a novel human CC chemokine liver and
 activation-regulated chemokine (LARC) expressed in liver.
 Chemotactic activity for lymphocytes and gene localization on
 chromosome 2
 J. Biol. Chem. 272 (9), 5846-5853 (1997)
 MEDLINE 97190319
 REFERENCE 2 (bases 1 to 799)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyaama,H.
 JOURNAL Unpublished (1996)
 REFERENCE 3 (bases 1 to 799)
 AUTHORS Nomiyaama,H.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyaama, Kumamoto University Medical School,

Department

of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiyaama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

FEATURES

Location/Qualifiers
 source 1..799
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="2"
 /map="q33-37"
 sig_peptide 59..136
 /gene="LARC"
 CDS 59..349
 /gene="LARC"
 /codon_start=1
 /product="CC chemokine LARC precursor"
 /db_xref="PID:d1013880"
 /db_xref="PID:g1871139"

```

/translation="MCCTKSLLLAALMSVLLHLCGESEASNFDCCLGYTDRLHPK
              FIVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKKVKNM"
gene          59..349
              /gene="LARC"
mat_peptide   137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT    240 a    138 c    153 g    268 t
ORIGIN
1  cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccaa
61 gtgctgtacc aagagtttgc tcctggctgc ttgatgtca gtgctgtac tccacctctg
121 cggcgaatca gaagcagcaa gcaactttga ctgctgtcct ggatacacag accgtattct
181 tcatacctaaa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
241 tgctatcatc ttccacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
301 ggtgaaatat attgtgctgc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
361 tttctggaat ggaattggac atagcccaag aacagaaaga acctgtctgg ggttggaggt
421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgct
481 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa
541 gttaaactgt attttatggt atttatagct gtaggttttc tgtgttttagc tatttaatac
601 taattttcca taagctatct tggtttagtg caaagtataa aatttatatt gggggggaat
661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
781 cattaataag acaaatatt

```

```

//
LOCUS          HUMAR          538 bp    mRNA          PRI          11-SEP-1996
DEFINITION     Human mRNA for chemokine, complete cds.
ACCESSION      D43767
NID            g1536878
KEYWORDS       chemokine, thymus and activation-regulated; chemokine.
SOURCE         Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
REFERENCE      1 (sites)
AUTHORS        Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
               Yoshie,O.
TITLE          Molecular cloning of a novel T cell-directed CC chemokine
expressed      in thymus by signal sequence trap using Epstein-Barr virus
vector
JOURNAL        J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE        96355526
REFERENCE      2 (bases 1 to 538)
AUTHORS        Imai,T.
JOURNAL        Unpublished (1996)
REFERENCE      3 (bases 1 to 538)
AUTHORS        Imai,T.
TITLE          Direct Submission
JOURNAL        Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio

```

```

FEATURES
source         1..538
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="D3A"
               /sex="male"
               /tissue_type="peripheral blood"
CDS            53..337
               /note="thymus and activation regulated"
               /codon_start=1
               /product="chemokine"
               /db_xref="PID:d1008410"
               /db_xref="PID:g1536879"

```

```

/translation="MAPLKMLALVTLGLGASLQHIHAARGTNVGRECCLEYFKGAIPL
              RKLKWTYQTSDEDCSRDAIVFVTVQGRAICSDPNNKRVKNVAVKYQLSLERS"

```

```

BASE COUNT      118 a      168 c      149 g      103 t
ORIGIN
    1 cccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
   61 actgaagatg ctggccctgg tcaccctcct cctgggggct tctctgcagc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaaag ctgaagacgt ggtaccagac atctgaggac tgcctcaggg atgccatcgt
  241 ttttgtaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctctcaccac cagactcctg
  361 actgtctccc gggactacct gggacctcca ccgttggtgt tcaccgcccc caccctgagc
  421 gcctgggtcc aggggaggcc ttccaggagc gaagaagagc cacagtgagg gagatcccat
  481 ccccttgctc gaactggagc catgggcaca aagggccagc attaaagtct ttatcctc
//

```

```

LOCUS      HUMEOTAXIN      807 bp      mRNA      PRI      25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION  D49372
NID        g1552240
KEYWORDS   eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE      Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
            Hominidae;
            Homo.
REFERENCE   1 (bases 1 to 807)
AUTHORS     Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
TITLE       Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
JOURNAL      J. Biol. Chem. 271 (13), 7725-7730 (1996)
MEDLINE     96205964
REFERENCE   2 (bases 1 to 807)
AUTHORS     Yoshie,O.
TITLE       Direct Submission
JOURNAL      Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
Osamu

```

```

Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)

```

```

COMMENT     On Sep 20, 1996 this sequence version replaced gi:1313900.

```

```

FEATURES
  source          1..807
                  /organism="Homo sapiens"
                  /db_xref="taxon:9606"
                  /clone="141"
                  /tissue_type="Small intestine, proximal"
  CDS             99..392
                  /codon_start=1
                  /product="eotaxin"
                  /db_xref="PID:d1008966"
                  /db_xref="PID:g1552241"

```

```

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
misc_signal      548..557
                  /note="mRNA destabilization signal"
polyA_signal     775..780
polyA_site       807

```

```

BASE COUNT      229 a      198 c      147 g      233 t
ORIGIN
    1 gcattttttc aagttttatg attttattaa cttgtggaac aaaaataaac cagaaaccac
   61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggctctc gcagcacttc
  121 tgtggctgct gctcatagca gctgccttca gcccccaggg gctcgctggg ccagcttctg
  181 tcccaaccac ctgctgcttt aaactggcca ataggaagat accccttcag cgactagaga
  241 gctacaggag aatcaccagt ggcaaatgtc ccagaaagc tgtgatcttc aagaccaaac
  301 tggccaagga tatctgtgcc gaccccaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggaccaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
  421 agcctgagtg ttgcctaatt tgtttccct tcttacaatg cattctgagg taacctcatt
  481 atcagtccaa agggcatggg ttttattata tatatatata tttttttttt aaaaaaaac
  541 gtattgcatt taatttattg aggcctttaa acttatcctc catgaatc atgtattttt

```

```

601 aaactgtaaa gctttgtgca gattctttac ccctgggag cccaattcg atccctgtc
661 acgtgtgggc aatgttcccc ctctcctctc ttcctccctg gaatcttgta aaggctctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttggaac ccaaagtgtg actcattaaa
781 tggaagtaaa tgttgtttta ggaatac

//
LOCUS      HSCCHEMA      232 bp      RNA      PRI      10-SEP-1996
DEFINITION H.sapiens mRNA for CC-chemokine.
ACCESSION  Z69291
NID        gl181148
KEYWORDS   CC-chemokine.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 232)
AUTHORS    Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
TITLE      Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
JOURNAL     Unpublished
REFERENCE  2 (bases 1 to 232)
AUTHORS     Bartels,J.H.
TITLE       Direct Submission
JOURNAL     Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet zu Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE  3 (bases 1 to 232)
AUTHORS     Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
TITLE       Human dermal fibroblasts express eotaxin: molecular cloning,
            mRNA
            expression, and identification of eotaxin sequence variants
JOURNAL     Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
MEDLINE     96374440
FEATURES
  source     Location/Qualifiers
            1..232
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone="clones 4(9512),
            14(9512),15(9512),10(9601),11(9601)"
            /tissue_type="foreskin"
            /cell_type="fibroblast"
            /sex="Male"
  mRNA       <1..>232
            /citation=[1]
            /product="CC-chemokine"
  sig_peptide 56..109
            /citation=[1]
  CDS         56..>232
            /function="putative chemoattractant protein"
            /note="sequence homology to human MCP-1, MCP-2 and
            MCP-3
            and to rodent eotaxins"
            /citation=[1]
            /codon_start=1
            /product="CC-chemokine, preprotein"
            /db_xref="PID:e221070"
            /db_xref="PID:gl181149"
            /db_xref="SWISS-PROT:P50877"
            /translation="MKVSAALLWLLIAAASPQGLAGPASVPTCCFNLANRKIPLQ
            RLESYRRITSGKCPQ"
  mat_peptide 110..>232
            /citation=[1]
            /function="putative chemoattractant protein"
            /product="CC-chemokine"
BASE COUNT  55 a      82 c      50 g      42 t      3 others
ORIGIN
      1 accaaaccag aaaccwccam ytctcagcc aaagctcaca ctttcagcct ccaacatgaa

```

61 ggtctccgca gcgcttctgt ggtgctgct catagcggt gccttcagcc cccaggggt
 121 cgctgggcca gcttctgtcc caaccactg ctgctttaac ctggccaata ggaagatacc
 181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag

```
//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS    Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
Knappe,P.
            and Forssmann,W.G.
TITLE      Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS    Pardigol,A.
TITLE      Direct Submission
JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower
            Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES   Location/Qualifiers
            source
            1..4037
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone="ph3b7"
            /dev_stage="adult"
            /tissue_type="placenta"
            /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
            /sex="male"
            TATA_signal
            727..733
            /note="putative, determined by consensus rules."
            5'UTR
            764..833
            /note="first base determined by means of consensus
rules"
            exon
            764..912
            /note="first base determined by means of consensus
rules;
            base 780 is the first base of cDNA (Z49270)"
            CDS
            join(834..912,3021..3135,3585..3672)
            /codon_start=1
            /product="chemokine HCC-1"
            /db_xref="PID:g1004267"
            /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRHGSVCTNPSPDKWVQDYIKDMKEN"
            intron
            913..3020
            /number=1
            exon
            3021..3135
            /number=2
            intron
            3136..3584
            /number=2
            exon
            3585..3817
            /number=3
            3'UTR
            3673..3817
BASE COUNT  1023 a   1048 c   1004 g   962 t
ORIGIN
      1 gagctccggt gggagtcacca tgtttcttta tggcataatg ggtgagaaca cagacttgga
      61 agccaaacca cctgaatttg aacccaggtt ccatttacca actgtcaaaa gcttaggctt
     121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
     181 ggcaactggg acagtggctt gtgtgtatag caaccattat ataagtgaat tatctactga
     241 gcaccacagc acttcttcac tccatgggtg ggtgaccaga atggagatga gacagagaac
     301 tgcaggttct gcttcgagtt taagtttaga tttcccttga ccaatgagac ctgacttgga
     361 ggagtccttg cctcattcca ttacccaaaa caccctctag tctctagatg aaagatcctt
     421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tgggaattgga tacaggacac
```



```

481 atccagcctt gagatctttt gctaagtgtg acacagtggc cccagccctg tgcctatgtt
541 catgcctagg gaaaggcttc tatcaaaaaga gttgaacttc tccccactgg ggatggaaga
601 ccatcttcctc ccttaaacct tggctctccc tgcttccctc aggccaccaa caacacatgt
661 gcaggatgatg aaattgctga ggcatcactg ctttctact tcccttccaa gtctcagctc
721 ccttatattta aaaaatattt ggcctcaatg atcatttctc aacaattcct caccgcaggga
781 gcctctgaag ctcccaccag gccagctctc ctcccacaac agcttcccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctccc tcatcaccat cgccctaggg accaagactg
901 aatcctcctc acgtgagtgc aatgccttgt cttccttcca acctagagcc tgcagggaaa
961 taagcaggag tgaggttggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctgggtatctt ctgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcccccctt ggtgtggtga gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagttaaag ttgggtatctt ccagccttga ccaatgagac ttgacttggg
1201 agactccagg cttcattcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct cttatcattg cccccaggga ccagtcctcc
1321 cttgccctca aggacatgga gtgagaccag cctgcctctc tactcctctc atttctctct
1381 ctttgccgct aagcaaaaga gtggcccacc ccatttgggg tatatttctc caggagagatt
1441 aggagcagtg tcttgagccc ctcaagggca ttttctatt ggctcctga ggttggggcc
1501 cagcctgctt ccagcgtcac ctgtgccag tgagtgcagc attgcttggg tatgggtctg
1561 ggggaaacac gacagtgtgg ggtccatcct aggccccctt ttctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta tttatcactc ttccatttta cctactctcc
1681 ttttcagaaa ctggggggaa accgaaggtt gttaaaatac agctaaagtt ggtgggtatg
1741 tgcacagtgt gacttgccct ctccgatgtc atttgcagc tcagaggaaac aaggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acagggggccc cttatgcccgt tctttggatc
1861 gtgaggatgc tgcctggaaat ggagctggaa aacaggatga gaccttcca cccagacatc
1921 tggccacctc cagtgcctc tgaggccatt gtgatgcaca tccatgattc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgcctgttt
2041 gtacagggct cttggcctac aatgtccttc ctgctacctc tataattcaa gcttgggggtg
2101 gctgctgtca ccttgctctt cctataaaag ccatgaaact tctcaatcag aaaaatagatg
2161 aaaaaatcac ccaatccagt gatttttaa aactttttaga ccacaaaacc ttttctcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggtaca
2281 agacaccact ctcaaatgca gcaaggcttc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaaaggc ctcatcttca gaggaggaaa cagggggaaa
2401 gtaaaatggc cacagtacac aggaagcaca ggcaagggtt ggttaggatt tgggtgccct
2461 gactctgtgg cctttgtctt tggggcttgc tgtgggcctc ctgctctctc tgcaggttgt
2521 cggttcaatg gggacatggg caggggtggag cactaggagg ggctgggttt gcattcccaa
2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat attcctccca tttggagcac
2641 ctttcccgaa taaggcatga aggctgcctg atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgccttcaa tcttgaggt
2761 gaaagtcatc caccagtctt tccaagaggg gttgaagaaa aggaggaaag gtgattgatg
2821 atgaggggag agaaaaagaa gagcccaggga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctcccctcc aagtctctgag gggctgtctc ctcttctctt cctcctcca
2941 tgccctcagc ttgcaggagc agccaatggg atggccttta acaaggggcc cttcctcagc
3001 atctgatgct ctctcctcag ggggacctta ccacctctca gactgctgct tcacctacac
3061 tacctacaag atcccgcgct agcggattat ggattactat gagaccaaca gccagtgtct
3121 caagcccgga attgtgtagg tggtaacacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gagggaagca gggagtgtgt gtggaatggg gacccccagc gtacctccca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgcttctt ggttggagcc
3301 tgcaggagcc atggggaaac tgacctcatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagaggg cacttctcca gggggacaca gagactagat ggggtctagg gtcttaggaa
3421 ccgaagagta tgtctcagag agggagactgg ctctaagctg cctctgtgga agaaggaaa
3481 agcagatatg gtcaggtggg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actgggcccc tcggtttgtg atccttctcc ctcttgctcc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa cccagtgac aagtgggtcc aggactatat caaggacatg
3661 aaggagaact gagtgaacca gaaggggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaagg ccccctctc caccacccgc taactctcag cccagtcac cctcttggag
3781 cttcctgctt ttgaattaaa gaccactcat gctcttccct ggccctcatc ctttctacgg
3841 gatttactca ttggccatgc actgaggaca ccaggggtgt gcaccctcgg catcaagcct
3901 cgctctcgag aagttttggt ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaa accgtctctc cctcagcagc
4021 aacagtagca gaccccg

```

//

```

LOCUS       HSCC21          925 bp      mRNA          PRI          30-JUN-1998
DEFINITION  H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION   Z70292
NID         g1296608
KEYWORDS    chemokine CC-1; chemokine CC-2.
SOURCE      human.
            ORGANISM      Homo sapiens
                        Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
                        Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 925)

```

AUTHORS Pardigol, A., Forssmann, U., Zucht, H.D., Loetscher, P.,
Schulz-Knappe, P., Baggiolini, M., Forssmann, W.G. and Magert, H.J.

TITLE HCC-2, a human chemokine: gene structure, expression pattern,
and biological activity

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)

MEDLINE 98263352

REFERENCE 2 (bases 1 to 925)

AUTHORS Pardigol, A.

TITLE Direct Submission

JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology, Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse 31, Hannover, Lower Saxony, 30625, Germany

FEATURES Location/Qualifiers

source 1..925
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="adult"
/tissue_type="liver"
/clone_lib="PCR fragments"

5'UTR 1..55

CDS 56..397
/note="putative; first coding region of a bicistronic
mRNA"
/codon_start=1
/product="chemokine CC-2"
/db_xref="PID:e233855"
/db_xref="PID:g1296609"
/db_xref="SWISS-PROT:Q16663"

/translation="MKVSVAAALSCLMLVAVLGSAQFTNDAETELMMSKLPLENPVVL
NSFHFAADCCTSYISQSI PCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
DCMKKLPYSI"

misc_feature 398..498
/note="spacing region between two coding regions of
the bicistronic mRNA"

CDS 499..780
/codon_start=1
/evidence="experimental"
/product="chemokine CC-1"
/db_xref="PID:e233856"
/db_xref="PID:g1296610"
/db_xref="SWISS-PROT:Q16627"

/translation="MKISVAAIPFFLLITIALGKTTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSPDKWVQDYIKDMKEN"

3'UTR 781..925

polyA_signal 902..908

BASE COUNT 240 a 296 c 199 g 190 t

ORIGIN

```

1 ccaggaagca gtagagccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
61 ggtctccgtg gctgccctct cctgccctcat gcttggtgct gtccttggtat ccagggccca
121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag ctccactgg aaaaaccagt
181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
241 ccggtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccaggtgt
301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa ccagtggtc cgaggattca
361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttccctctct cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcttcacggg gaccttacca cccctcagag
601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
661 accaacagcc agtgctccaa gcccgaatt gtcttcatca ccaaaaaggg ccatttcgct
721 tttaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
781 gtgacccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
841 cctcctcca cccaccgcta actctcagcc ccagtcaccc tcttgagct tccctgcttt
901 gaattaaaga ccactcatgc tcttc

```

//

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol, A., Maegert, H.J., Zucht, H.D., Forssmann, W.G. and
 Schulz-Knappe, P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol, A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAALSCMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSI PCSLMKSYFETSSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFFLLITIALGKTTESSQTGGKPKVVKIQLKLVG
 PYHPSECCFTYTTYKIPRQRIMDYETNSQCSKPGIVFITKRHGSVCTNP SDKWVQDY
 IKDMKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgcctct cctgcctcat gcttggtgct gtccttgat ccaggccca
 121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
 241 cccgtgttca ctcatgaaa gttattttga aacgagcagc gagtgctcca agccaggtgt
 301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa ccagtggtc cgggagttca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccaccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc

```

481 acaacagctt cccacagcat gaagatcttc gtggctgcca ttcccttctt cctcctcacc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctggggggaa accgaagggtt
601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgcttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaagggggc attccgtctg taccaacccc
781 agtgacaagt ggtgccagga ctatatcaag gacatgaagg agaactgagt gacccagaag
841 ggggtggcga ggacacagctc agagacataa agagaagatg ccaaggcccc ctccctcacc
901 caccgctaac tctcagcccc agtcacccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      1430 bp      mRNA                      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL     Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES
  source    Location/Qualifiers
            1..1430
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /chromosome="17"
  gene      1..1430
            /gene="HCC-4"
  CDS       1..363
            /gene="HCC-4"
            /note="CC or beta chemokine family member"
            /codon_start=1
            /product="IL-10-inducible chemokine"
            /db_xref="PID:g2581781"

```

```

/translation="MKVSEAAALSLVLILIITSASRSQPKVPEWVNTPTCCLKYYEK

```

```

VLPRRLVVGyrKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYIKDPNLPLLPTRNLS
TVKIITAKNGQPQLNSQ"

```

```

BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN

```

```

1 atgaaggctc cccaggctgc cctgtctctc cttgtctcca tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgct taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatgggtcaac cccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattagcg tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagagggtac gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcaccg aggctggagt gcagtgtgtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gctcccagag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt ttttgatttt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggc tcaaactcgt gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctctct ctctcttcca attcctcact
961 tcacaccagt acacaagcca ttctaataac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat tttctggat ctatattttc ttcaattatt ctttcatttt ataatgcaac

```

```

1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactcctc tatttgacaa

```

//

```

LOCUS      AB007454      1503 bp      mRNA                      PRI      09-APR-1998
DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
ACCESSION  AB007454
NID        g2723285
KEYWORDS   chemokine LEC precursor.
SOURCE      Homo sapiens liver cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (sites)
AUTHORS     Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
            Yoshie,O. and Nomiya,H.
TITLE       Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
JOURNAL      Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
MEDLINE      98207719
REFERENCE   2 (bases 1 to 1503)
AUTHORS      Nomiya,H.
TITLE        Direct Submission
JOURNAL      Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department  of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
Japan        (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)

```

```

FEATURES             Location/Qualifiers
     source            1..1503
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /tissue_type="liver"
     sig_peptide       77..145
     CDS               77..439
                       /codon_start=1
                       /product="chemokine LEC precursor"
                       /db_xref="PID:d1024963"
                       /db_xref="PID:g2723286"

```

/translation="MKVSEAAALSLVLILIITSASRSQPKVPEWVNTPTCCLKYYEK

```

VLPRRLVVGyrKALNCHLPAIIFVTKRNRVCTNPNDWVQEIYKDPNLPPLPTRLNS
TVKIIITAKNGQPQLLSQ"

```

```

mat_peptide  146..436
polyA_signal 560..565
polyA_signal 1485..1490

```

```

BASE COUNT      417 a      374 c      312 g      400 t
ORIGIN

```

```

1  gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tctctatcct
121 tatcattact tcggcttctc gcagccagcc aaaagttcct gactgggtga acacccatc
181 cacctgctgc ctgaagtatt atgagaaagt gttgccaaagg agactagtga tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac ccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
421 gctcctcaac tcccagtgat gaccaggctt tagtggaagc ccttggttac agaagagagg
481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtatttcga atattttctc aatcttagga
601 ggaataacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgca gtggtgtgat
721 cttggctcac ttgatcttgg ctcaactgtaa cctccacctc ccaggctcaa gtgatcctcc
781 caccaccagc tcccagtag ctgggactac aggccttgcc caccacactt ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tgttgccag gctggtctca aactcgtgtg
901 cccaagcaat ccactgcct cagccttcca aaagtgtgg gattacaggc gtgagccacc
961 acatccggcc agtgactct taatacacag aaaaaatata ttcacatctc tctcctgtcc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

1081 agccttccag atgatctttg cctctgggt cttgacccat taagagcccc atagaactct
1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
1201 tcattttata atgcaacttt ttcattaggaa gtccggatgg gaattattcac attaatcatt
1261 tttgcagaga ctttgctaga tcctctcata ttttgcttc ctcaggggtg caggggtaca
1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
1381 acacaaatct ctacctccca tgttaagctt tgcaggacag ggaaagaaag ggtatgagac
1441 acggctaggg gtaaactctt agtccaaaac ccaagcatgc aataaataaa actcccttat
1501 ttg

```

//

```

LOCUS      AF001979      800 bp      mRNA      PRI      20-NOV-1997
DEFINITION Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION  AF001979
NID        g2624924
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
JOURNAL     J. Immunol. 159 (4), 1589-1593 (1997)
MEDLINE     97400322
REFERENCE  2 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Direct Submission
JOURNAL     Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..800
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS          1..405
                        /note="6Ckine; CC chemokine"
                        /codon_start=1
                        /product="beta chemokine"
                        /db_xref="PID:g2624925"

```

/translation="MAQSLALSLILVLAFGIPRTQGSDDGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGCSSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGKCKRTSQTTPKGP"

```

BASE COUNT      203 a      248 c      210 g      139 t
ORIGIN
1 atggctcagt cactggctct gagcctcctt atcctgggtc tggcctttgg aatccccagg
61 acccaaggca gtgatggagg ggctcaggac tggtgcctca agtacagcca aaggaagatt
121 ccgcaccaag ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga cccaaaggag
241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
301 cagggtgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
361 ggctgcaaga ggactgagcg gtcacagacc cctaaagggc catagcccag tgagcagcct
421 ggagccctgg agacccacc agcttcacca gcgcttgaag cctgaaccca agatgcaaga
481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactcttt
541 ctctgtcttt aaccacccca tctgcattcc cagctctacc ctgcatggct gagctgccc
601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccaggagaca tgagaggagg
661 cagcaggact gtccccttga aggagaatca tcaggaccct ggacctgata cggctcccca
721 gtacacccca cctcttcctt gtaaatatga tttataccta actgaataaa aagctgttct
781 gtcttccac ccaaaaaaa

```

//

```

LOCUS      HSU64197      821 bp      mRNA      PRI      25-JUN-1997
DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION  U64197
NID        g1778716
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

```

Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE 1 (bases 1 to 821)
AUTHORS Hromas, R., Gray, P.W., Chantry, D., Godiska, R., Krathwohl, M.,
Fife, K., Bell, G.I., Takeda, J., Aronica, S., Gordon, M.,
Cooper, S., Broxmeyer, H.E. and Klemsz, M.J.
TITLE Cloning and characterization of exodus, a novel beta-chemokine
JOURNAL Blood 89 (9), 3315-3322 (1997)
MEDLINE 97275143
REFERENCE 2 (bases 1 to 821)
AUTHORS Hromas, R.A.
TITLE Direct Submission
JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
FEATURES Location/Qualifiers
source 1..821
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Exodus-1"
/cell_type="islet"
/tissue_type="pancreas"
/dev_stage="adult"
CDS 43..330
/function="inhibits proliferation of hematopoietic
progenitors and HIV"
/codon_start=1
/product="chemokine exodus-1"
/db_xref="PID:gl778717"
/translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRILHPKF
IVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
variation 121^122
/insertion of an extra codon GCA at nt 121,
encoding for an alanine after the alanine at amino acid
position 26, represents the allelic difference of the
transcript isolated from macrophages"
BASE COUNT 258 a 134 c 156 g 273 t
ORIGIN
1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
61 ttgctcctgg ctgctttgat gtcagtgtct ctactccacc tctgcggcga atcagaagca
121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
301 ctccctcagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tggaattgga
361 catagcccaa gaacagaaaag aaccttgctg gggttggagg ttccacttgc acatcatgga
421 gggtttagtg cttatctaatt ttgtgcctca cctggacttg tccaattaat gaagttgatt
481 catattgcat catagtttgc ttgttttaag catcacatta aagtgaact gtattttatg
541 ttatttatag ctgtaggttt tctgtgttta gctatttaatt actaattttc cataagctat
601 tttggttttag tgcaaatgat aaaattatat ttggggggga ataagattat atggactttc
661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
781 ttgaaaataa agaaacaaa agtgcttctg ttaaaaaaaa a
//
LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
ACCESSION U88320
NID g2196919
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 828)
AUTHORS Hromas, R., Kim, C.H., Klemsz, M., Krathwohl, M., Fife, K.,
Cooper, S.,

TITLE Schnizlein-Bick,C. and Broxmeyer,H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"
 /translation="MAQSLALSLLILVLAFGIPRTQGSDDGAQDCCLKYSQRKIPAKV
 VRSYRKQEPSLGCSPAILFLPRKRSQAEKADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKKGKSGCKRTERSQTPKGP"
 BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN
 1 ggcacgagggc agacatggct cagtcactgg ctctgagcct ccttaccctg gttctggcct
 61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
 121 gccaaaggaa gattccccgc aagggttgcc gcagctaccg gaagcaggaa ccaagcttag
 181 gctgctccat cccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
 241 cagacccaaa ggagctctgg gtgcagcagc tgatgcagca tctggacaag acaccatccc
 301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaaag
 361 gaaaggggctc caaaggctgc aagaggactg agcggtcaca gaccctctaa gggccatagc
 421 ccagttagca gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
 481 cccaagatgc aagaaggagg ctatgtctag gggccctgga gcagccaccc catgctggcc
 541 ttgccacact ctttctctg ctttaaccac cccatctgca ttcccagctc tcaccctgca
 601 tggctgagtc tgcccacagc aggccagggtc cagagagacc gaggaggagc agtctccagc
 661 ggagcatgag aggagcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
 721 ctgatacggc tccccagtac accccacctc ttccttgtaa atatgattta tacctaactg
 781 aataaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaaaa
 //
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas,R.A., Gray,P., Klemsz,M., Fife,K. and Broxmeyer,H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502


```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
CDS
120..416
/note="Mip-3alpha/ELC/CKbeta11"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

/translation="MALLLALSLLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      113 a      170 c      121 g      98 t
ORIGIN
    1 ctcacacctt gcatttcacc cctgcatccc atgcgccttg cagcctcaca cagatcctgc
   61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
  121 tggcctgct actggccctc agcctgctgg ttctctggac ttcccagcc ccaactctga
  181 gtggaccaa tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
  241 acatcgtgag gaacttcac taccttctca tcaaggatgg ctgcaggggt cctgctgtag
  301 tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
  361 gcatcatcca gagactgcag aggacctcag ccaagatgaa gcgccgcagc agttaaccta
  421 tgaccgtgca gagggagccc cgagtccgag tcaagcattg tgaattatta ctaactggga
  481 acgaggacag aaggaaggac ag
//

LOCUS      HSU86358      879 bp      mRNA      PRI      11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION  U86358
NID        g2388626
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 879)
AUTHORS    Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P., Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
and
            Zlotnik,A.
TITLE      TECK: a novel cc chemokine specifically expressed by thymic
            dendritic cells and potentially involved in T cell development
JOURNAL    Immunology 7, 291-301 (1997)
REFERENCE  2 (bases 1 to 879)
AUTHORS    Vicari,A.P. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901
            California Ave., Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..879
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /tissue_type="thymus"
            gene        1..879
                        /gene="TECK"
            CDS          1..453
                        /gene="TECK"
                        /codon_start=1
                        /product="chemokine"
                        /db_xref="PID:g2388627"

/translation="MNLWLLACLVLGAWAPAVHTQGVFEDCCLAYHYPIGWAVLR

RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCNPKSREVQRAMKLLDARNKVFAKLHH
NMQTFQAGPHAVKLLSSGSKLSSSKFSNPISSSKRNVSLLISANSGL"
BASE COUNT      191 a      264 c      218 g      206 t

```

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctgggtg gccggcttcc tgggagcctg ggcccccgct
61 gtccacaccc aagggtgtctt tgaggactgc tgcctggcct accactaccc cattgggtgg
121 gctgtgctcc ggcgcgctcg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct ccccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggagggtg agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagcgggct catttctggg ctccatcggc
481 acaggagggg ccggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgctctgtc ttttgggtca agtcttaate cctgcacctg agttggtcct ccctctgcac
601 cccaccacc tctgcccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgccgctcc ggggaacagc acaatcctgg gcagccagtg gctctttagt agaaaactta
721 ggatacctct ctcaactttt gtttcttgcc gtccaccccg ggccatgcca gtgtgtctc
781 tgggtccctt ccaaaaatct ggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE      Homo sapiens cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE   1 (bases 1 to 852)
AUTHORS     Nomiya, H.
TITLE        Direct Submission
JOURNAL      Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department  of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2 (bases 1 to 852)
AUTHORS     Nagira, M., Imai, T., Hieshima, K., Kusuda, J., Ridanpaa, M.,
            Takagi, S.,
TITLE        Nishimura, M., Kakizaki, M., Nomiya, H. and Yoshie, O.
            Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL      Unpublished (1997)
FEATURES    Location/Qualifiers
            source          1..852
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS              59..463
                        /codon_start=1
                        /product="SLC"
                        /db_xref="PID:d1022673"
                        /db_xref="PID:g2335035"
            /translation="MAQSLALSLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV
VRSYRKQEPSLGCSSIPAILFLPRKRSQAEKLPKELWVQQLMQHLDKTPSPQKPAQG
            mat_peptide      CRKDRGASKTGKKGKSGKCKRTERSQTPKGP"
                        <107..460
                        /product="mature ELC"
            polyA_site        823..828
BASE COUNT   205 a      279 c      217 g      151 t
ORIGIN
1 cttgcagctg cccacctcac cctcagctct ggctctttac tcaccttcta ccacagacat
61 ggctcagtc ctggctctga gctctcttat cctggttctg gcctttggca tccccaggac
121 ccaaggcagt gatggagggg ctccaggactg ttgcctcaag tacagcaaaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggtgtgt ccatccagc
241 tatcctgttc ttgccccgca agcgctctca ggcagagcta tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcca tagccagtg agcagcctgg
481 agccctggag accccaccag cctcaccaac gcttgaagcc tgaacccaag atgcaagaag
541 gaggctatgc tcaggggccc tggagcagcc accccatgct ggccttgcca cactctttct
601 cctgctttaa ccaccccatc tgcattccca gctctaccct gcatggctga gctgcccaca
661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctccccagt
781 acacccacc tcttcttgt aatatgatt tatacctaac tgaataaaaa gctgttctgt
841 cttcccacc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocytic chemoattractant human CC chemokine, with
            myelosuppressive activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS    Youn,B.S. and Kwon,B.S.
TITLE      Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
            Science Bldg., Indianapolis, IN 46202, USA
FEATURES    Location/Qualifiers
            source          1..1481
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            5'UTR          1..34
            CDS             35..397
                        /note="Mtn-1; LMC; lymphocyte and monocytic
            chemoattractant CC chemokine"
                        /codon_start=1
                        /product="monotactin-1"
                        /db_xref="PID:g3395776"

```

/translation="MKVSEAAALLVLILITSSASRSQPKVPEWVNTPTSCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNRVCTNPNDWVQEYIKDPNLPPLPTRNLS

TVKIIITAKNGQPQLLNSQ"

3'UTR 398..1481

BASE COUNT 412 a 362 c 302 g 405 t

ORIGIN

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgct ctcatectta tcattacttc ggcttctcgc agccagccaa aagtctctga
121 gtgggtgaac accccatcca cctgctgcct gaagtattat gagaaagtgt tgccaaggag
181 actagtgggt ggatacagaa aggcctctca ctgtcacctg ccagcaatca tcttcgtcac
241 caagaggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaa agtacatcaa
301 ggatcccaac ctacctttgc tgcctaccag gaacttgctc acggttaaaa ttattacagc
361 aaagaatggt caacccacgc tctcaactc ccagtgtatga ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttcgaata
541 tttctcfaat cttaggagga aataccaaag ttaagggagc tgggcagagg tacgctcttt
601 tatttttata tttatatttt tatttttttg agatagggtc ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccacctccca
721 ggctcaagtg atctctccac cccaccctcc cgagttagct ggactacagg cttgcgcac
781 cacacctggc taatttttgt atttttggta gagacgggat tctaccatgt tgcccaggct

```

```

841 ggctctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgctg agccaccaca tccggccagt ccactcttaa tacacagaaa aatataatttc
961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc cttccagatg atctttgccc tctgggtctt gacccattaa
1081 gagccccata gaactcttga ttttctctgt ccactcttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtagggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttctt
1261 caggggtggca ggggtacaga agtgcttgat tggttttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacagggga
1381 aagaaaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc ctttatttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS       HSRNAATAC      557 bp      RNA              PRI      06-JUL-1995
DEFINITION  H.sapiens mRNA for ATAC protein.
ACCESSION   X86474
NID         g895846
KEYWORDS    ATAC gene.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 557)
  AUTHORS   Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and Kroczeck,R.A.
  TITLE     Cloning of ATAC, an activation-induced, chemokine-related
  molecule
            exclusively expressed in CD8+ T lymphocytes
  JOURNAL   Eur. J. Immunol. 25 (6), 1744-1748 (1995)
  MEDLINE   95339892
  REFERENCE 2 (bases 1 to 557)
  AUTHORS   Kroczeck,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (20-APR-1995) R.A. Kroczeck, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES             Location/Qualifiers
     source           1..557
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="peripheral blood"
                     /cell_type="lymphocyte"
                     /chromosome="1"
                     /map="q23"
     gene             25..369
                     /gene="ATAC"
     CDS              25..369
                     /gene="ATAC"
                     /codon_start=1
                     /product="CD8+T cell specific protein"
                     /db_xref="PID:g895847"
                     /db_xref="SWISS-PROT:P47992"

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTC VSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT

QQSTNTAVTLTG"

polyA_signal 469..474

polyA_signal 534..539

BASE COUNT 157 a 139 c 112 g 149 t

ORIGIN

```

1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
61 tctctcactg catacattgt ggaaggtgta gggagtgaag tctcagataa gaggacctgt
121 gtgagctca ctacccagcg actgcccgtt agcagaatca agacctacac catcacggaa
181 ggctccttga gaggagtaat ttttattacc aaacgtggcc taaaagtctg tggatctcca
241 caagccacat gggtagagaga cgtggtcagg agcatggaca ggaaatccaa caccagaaat
301 aacatgatcc agaccaagcc aacaggaacc cagcaatcga ccaatacagc tgtgactctg
361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttcactttac
421 acgctcatgg actgagttta tactgcctt ttatgaaagc actgcatgaa taaaattatt
481 cctttgtatt ttacttttta aatgtcttct gtattcactt atatgttcta attaataaat
541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA,
 complete
 cds.
 ACCESSION U85767
 NID gi916249
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
 Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
 Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-
 C chemokines as inhibitors of two distinct classes of myeloid
 progenitors
 JOURNAL J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences,
 9410
 Keywest Ave., Rockville, MD 20850, USA
 FEATURES Location/Qualifiers
 source 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:gi916250"

/translation="MKVSVAAALSCMLVLTALGSQARVTKDAETEFMMSKLPLENPVLL

DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
 QVCMRMLKLDTRIKTRKN"

BASE COUNT 164 a 143 c 117 g 139 t
 ORIGIN

```

1 ctcagccagc cctgcctgcc caccaggagg atgaaggtct ccgtggctgc cctctcctgc
61 ctcagcttg ttactgccct tggatccag gcccggtca caaaagatgc agagacagag
121 ttcagatgt caaagcttcc attggaatat ccagtacttc tggacagatt ccatgctact
181 agtgctgact gctgcatctc ctacacccca cgaagcatcc cgtgttcact cctggagagt
241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
301 cgacgtttct gtgccaaccc cagtataaag caagttcagg tttgcatgag aatgctgaag
361 ctggacacac ggatcaagac caggaagaat tgaacttgtc aaggtgaagg gacacaagtt
421 gccagccacc aactttcttg cctcaactac cttcctgaat tattttttta agaagcattt
481 attcttggtg tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
541 aaaaaaaaaa aaaaaaaaaa aaa

```

//

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA,
 complete
 cds.
 ACCESSION U85768
 NID gi916251
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
 Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
 Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors

J. Exp. Med. (1997) In press

REFERENCE 2 (bases 1 to 360)

AUTHORS Li, H. and Patel, V. P.

TITLE Direct Submission

JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410

Keywest Ave., Rockville, MD 20850, USA

FEATURES

source Location/Qualifiers

1..360

/organism="Homo sapiens"

/db_xref="taxon:9606"

CDS

1..360

/note="myeloid progenitor inhibitory factor-2"

/codon_start=1

/product="MPIF-2"

/db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIIP TGSVVIPSCCMFFVSKRIPE

NRVVS YQLSSRSTCLKGGVIFTTKKGQFCGDPKQEWVQRYMKNLDAKQKKASPRARA

VAVKGPVQRYPGNQTTTC"

BASE COUNT 85 a 106 c 96 g 73 t

ORIGIN

1 atggcaggcc t gatgaccat agtaaccagc cttctgttcc ttggtgtctg tgccccaccac

61 atcatcccta cgggctctgt ggtcataccc tctccctgct gcatgttctt tgtttccaag

121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgcctcaag

181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag

241 tgggtccaga ggtacatgaa gaacctggac gccaaagcaga agaaggcttc ccctagggcc

301 agggcagtg cgtgcaagg ccctgtccag agatattcctg gcaaccaaac cacctgctaa

//

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996

DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds.

ACCESSION L36034

NID g1220363

KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating factor

homologue; alpha-chemokine.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1847)

AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H., Shinohara, T. and Honjo, T.

TITLE Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene

JOURNAL Genomics 28 (3), 495-500 (1995)

MEDLINE 96039262

FEATURES

source Location/Qualifiers

1..1847

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="h5"

/cell_line="FLEB14-14"

sig_peptide

80..142

/gene="SDF1a"

CDS

80..349

/codon_start=1

/product="pre-B cell stimulating factor homologue"

/db_xref="PID:g1220364"

/translation="MNAKV VVLVL TALCLSDGKPVSLSYRCP CRFFESHVARANV

KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"

gene

80..346

/gene="SDF1a"

mat_peptide

143..346

```

/gene="SDF1a"
/product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
1  tctccgctcag cgcgattgcc cgctcggcgt cgggcccccg acccgtgctc gtccgcccgc
61  ccgcccgcgc gcccgcgcca tgaacgcca ggtcgtgggc gtgctgggcc tcgtgctgac
121 cgcgctctgc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactcctaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
361 aaaaaggact ttccgctaga cccactcgag gaaaactaaa acctgtgtag agatgaaagg
421 gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
481 cattgatctg ggatcgggcc tgaggtttgc agcattttaga ccctgcattt atagcatacg
541 gtatgatatt gcagcttata ttcatccatg ccctgtacct gtgcacgttg gaacttttat
601 tactgggggt tttctaagaa agaaattgta ttatcaacag ctttttcaag cagttagtct
661 cttcatgatc atcacaaatc tcatcattct cattctcatt ttttaaatca acgagtactt
721 caagatctga atttggttg tttggagcat ctctctgtct cccctgggga gtctgggcac
781 agtcagggtg tggcttaaca gggagctgga aaaagtgtcc tttcttcaga cactgaggct
841 cccgcagcag cgcctctccc aagaggaagg cctctgtggc actcagatac cgactggggc
901 tggggcgccg ccactgcctt cacctctctt ttcaaaccctc agtgattggc tctgtgggct
961 ccattgtaga gccactatta ctgggactgt ctcagagacc cctctcccag ctattcttac
1021 tctctcccgc actccgagag catgcttaat cttgcttctg cttctcattt ctgtagcctg
1081 atcagcgccg caccagccgg gaagagggtg attgctgggg ctgctgccct gcacccctct
1141 cctcccaggc cctgccccac agctcggggc ctctgtgaga tccgtctttg gcctcctcca
1201 gaattggagc ggcctctctc tggggatgtg taatgggtccc cctgcttacc cgcaaaagac
1261 aagtctttac agaatacaat gcaattttaa atctgagagc tgccttgagt gactgggttt
1321 gtgattgcct ctgaagccta tgtatgccat ggaggcacta acaaactctg aggtttccga
1381 aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccactacccc ctccgtgaagc
1441 cacagcaggg gttcagggtc caatcagaac tgttggaagc gtgacatttc catgcataga
1501 tgcgatccac agaagggtct ggtggtatgt gtaacttttt gcaaggcatt tttttatata
1561 tatttttttg cacatttttt tttagcattc tttagaaaac aaatgtatgt caaaatatat
1621 ttatagtcga acaagtctata tatatgaatg agagccatat gaatgtcagt agttttatct
1681 tctctattat ctcaaaactac tggcaatttg taaagaaata tatatgatat ataaatgtga
1741 ttgcagcttt tcaatgttag ccacagtgtg ttttttcact tgtactaaaa ttgtatcaaa
1801 tgtgacatta tatgcactag caataaaatg ctaattgttt catggta

```

```

LOCUS      HUMSDF1B      3524 bp      mRNA      PRI      26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
complete cds.
ACCESSION  L36033
NID        g1220365
KEYWORDS   intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
SOURCE      human.
ORGANISM    Homo sapiens
REFERENCE   1 (bases 1 to 3524)
AUTHORS     Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
Shinohara,T. and Honjo,T.
TITLE       Structure and chromosomal localization of the human stromal
cell-derived factor 1 (SDF1) gene
JOURNAL     Genomics 28 (3), 495-500 (1995)
MEDLINE     96039262
FEATURES
source      Location/Qualifiers
            1..3524
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone="h17"
            /cell_line="FLEB14-14"
sig_peptide 80..142
            /gene="SDF1b"
CDS         80..361
            /codon_start=1
            /product="pre-B cell stimulating factor homologue"
            /db_xref="PID:g1220366"
            /translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
            KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM"

```

```

gene      80..358
          /gene="SDF1b"
mat_peptide 143..358
          /gene="SDF1b"
          /product="pre-B cell stimulating factor homologue"
BASE COUNT 903 a 886 c 793 g 942 t
ORIGIN
1 tctccgtcag cgcattgcc cgtcggcgt cgggccccg acccgtgtc gtccgccccg
61 cgcgccgccc gcccgcgcca tgaacgcca ggctgtggtc gtgctgtgac tctgtgtgac
121 cgcgtctgtc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgcccatt
181 cttcgaaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
361 agaggggtcag acgcctgagg aaccttaca gtaggagccc agctctgaaa ccagtgttag
421 ggaagggcct gccacagcct cccctgccag ggcagggccc caggcattgc caagggcttt
481 gttttgcaca ctttgcata ttttcacat ttgattatgt agcaaaatag atgacattta
541 tttttcattt agtttgatta ttcagtgtca ctggcgacac gtacgagctt agactaaggc
601 cattattgta cttgccttat tagagtgtct tcccacggag ccactcctct gactcagggc
661 tcctgggttt tgtattctct gagctgtgca ggtggggaga ctgggctgag ggagcctggc
721 cccatgggtc gccctagggg ggagagccac caagagggac gcctgggggt gccaggacca
781 gtcaacctgg gcaaaagccta gtgaaggctt ctctctgtgg gatgggatgg tggagggccca
841 catgggaggg tcacccctct ccccatccac atgggagccg ggtctgcctc ttctgggagg
901 gcagcagggc taccttgagc tgaggcagca gtgtgaggcc agggcagagt gagaccagc
961 cctcatcccg agcaccctca cctctccac gttctgtcta tcattctctg tctcatccat
1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaagct
1081 ttcattgtaa ctgtgcacca agcaggaaat gaaaatgtct tgtgttacct gaaaacactg
1141 tgcacatctg tgtcttgtgt ggaatatgtt ccattgtcca atcctatggt tttgtcaaaa
1201 gccagcgtcc tctctgtgta ccaatgtctt gatgcagca ctgttcccc tgtgcagccg
1261 ctgagcgagg agatgtctct tgggcccctt gagtgacgtc ctgatcagag ccgtgggtct
1321 ttgggggtgaa ctaccttggg tccccactg atcacaaaaa catgggtggg ccatgggagc
1381 agcccaaggg aattcgggtg gcaccagggt tgaccccgag ggattgtctg cccatcagtg
1441 ctccctcaca tgtcagtacc ttcaaaactag ggccaagccc agcactgctt gaggaaaaca
1501 agcattcaca acttggtttt ggtttttaaa acccagtcga caaaataacc aatcctggac
1561 atgaagattc tttcccaatt cacatctaac ctcatctctc tcaccatttg gcaatgccat
1621 catctcctgc cttctctctg ggccctctct gctctgcgtg tcacctgtgc ttccggccct
1681 tcccacagga catttctcta agagaacaat gtgctatgtg aagagtaagt caactgtcct
1741 gacatttgga gtgttcccc cccactgagg gcagtcgata gagctgtatt aagccactta
1801 aaatgttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgttt ttcatcagt
1861 cttacgaata cttttgccct ttgattaaag actccagtta aaaaaatttt taatgaagaa
1921 agtggaaaac aaggaagtca aagcaaggaa actatgtaac atgtaggaag taggaagtaa
1981 attatagtga tgtaatcttg aattgttaact gttcgtgaat ttaataatct gtagggtaat
2041 tagtaacatg tgttaagtat ttccataagt atttcaaat ggagcttcat ggcagaaggc
2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc cagctatggt
2161 atattgaaaa aatagagcct gagggatctt tactagtatt aaagatacag aactctttca
2221 aaaccttttg aaattaacct ctactataac cagtataatt gagttttcag tggggcagtc
2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttgga tgtacctgcc
2341 cccaatccat gaaccaagac cattgaattc ttgggtgagg aaacaaacat gaccctaaat
2401 cttgactaca gtcaggaaaag gaatcatttc tatttctcct ccatgggaga aaatagataa
2461 gtagtagaac tgcagggaaa attatttgca taacaattcc tctactaaca atcagctcct
2521 tcttgagagc tgcccagcta aagcaatatg catttaataa cagtcttcca tttgcaaggg
2581 aaaagtctct tgtaatccga atctcttttt gctttcgaac tgctagtcaa gtgcgtccac
2641 gagctgttta ctagggatcc ctcatctgtc cctccgggac ctgggtgtgc ctctacctga
2701 cactcccttg ggtccctgtt aacctcttca gaggccctcg ctgccagctc tgtatcagga
2761 cccagaggaa ggggccagag gctcgttgac tggctgtgtg ttgggattga gtctgtgcca
2821 cgtgtatgtg ctgtggtgtg tccccctctg tccaggcact gagataccag cgaggaggct
2881 ccagagggca ctctgcttgt tattagagat tacctcctga gaaaaaagct tccgcttgga
2941 gcagaggggc tgaatagcag aagggtgcac ctcccccaac cttagatggt ctaagtcttt
3001 ccattggatc tcattggacc cttccatggt gtgatcgtct gactggtgtt atcaccgtgg
3061 gctccctgac tgggagttga tcgccttttc cagggtgtac acccttttcc agctggatga
3121 gaatttgagt gctctgatcc ctctacagag cttccctgac tcattctgca ggagccccat
3181 tcttgggaaa tattccctag aaacttccaa atccctaaag cagaccactg ataaaaccat
3241 gtagaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
3301 actgttttaa tgtgatgaat actgtatttt gtattgtttc aagtgcactc ccagataaat
3361 gtgaaaatgg tccaggagaa ggccaattcc tatacgcagc gtgctttaaa aaataaataa
3421 gaaacaactc tttgagaaac aacaatttct actttgaagt cataccaatg aaaaaatgta
3481 tatgcactta taattttcct aataaagttc tgtactcaaa tgta

```

//

```

LOCUS      HSJ002211      663 bp      mRNA      PRI      11-MAR-1998
DEFINITION Homo sapiens cDNA for a CXC chemokine.
ACCESSION  AJ002211

```


NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler,D.F., Loetscher,M., Roos,R.S., Clark-Lewis,I.,
 Baggiolini,M.

and Moser,B.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via

BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser,B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND

FEATURES Location/Qualifiers
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"

/translation="MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIP

RRFIDRIQILPRGNGCPRKEIIVWKKNKSIVCVDPQAEWIIQRMMEVLRKRSSSTLPVP

gene VFRRKIP
 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"

BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN

```

1  cagagctcaa gctcgaactc tacctccaga cagaatgaag ttcattctcga catctctgct
61  tctcatgctg ctggtcagca gcctctctcc agtccaaggt gttctggagg tctattacac
121 aagcttgagg tgtagatgtg tccaagagag ctcaagtctt atccctagac gcttcattga
181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
241 gaagaacaag tcaattgtgt gtgtggacct tcaagctgaa tggatacaaa gaatgatgga
301 agtattgaga aaaagaagtt cttcaactct accagttcca gtgtttaaga gaaagattcc
361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaataaagg
481 catgaggact atgtaaaaat aaccttgacg gagctggatg gggggccaaa ctcaagcttc
541 tttcactcca caggcacctt attntacact tgggggtttt gcnttctttn tttcntcagg
601 gggggggaaa gtttcttttg gaaantagtt nttccagttt ttaggtatta cagggttntt
661 ttt

```

//

LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber,J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of
USA
REFERENCE 2 (bases 1 to 2545)
AUTHORS Farber, J.M.
TITLE HuMig: a new human member of the chemokine family of cytokines
JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE 93236577
FEATURES
 source Location/Qualifiers
 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNQVQTCNLNPDSDVKELIKKWEKQVSQKKKQKNG
KKHQKKKVLKVRKSQRSRQKKTT"

BASE COUNT	755 a	581 c	457 g	752 t		
ORIGIN	1 atccaataca	ggagtgactt	ggaactccat	tctatcacta	tgaagaaaag	tggtgttctt
	61 ttccctcttg	gcattcatctt	gctgggtctg	attggagatgc	aaggaacccc	agtagtgaga
	121 aagggtcgct	gttcctgcat	cagcaccaac	caagggaacta	tccacctaca	atccttgaaa
	181 gaccttaaac	aatttgcccc	aagcccttcc	tgcgagaaaa	ttgaaatcat	tgctacactg
	241 aagaatggag	ttcaaacatg	tctaaaccca	gattcagcag	atgtgaagga	actgattaaa
	301 aagtgggaga	aacaggtcag	ccaaaagaaa	aagcaaaaaga	atgggaaaaa	acatcaaaaa
	361 aagaaagttc	tgaagttcgg	aaaatctcaa	cggtctcgct	aaaagaagac	tacataagag
	421 accacttcac	caataagtat	tctgtgttaa	aaatgttcta	ttttaattat	accgctatca
	481 ttccaaaagga	ggatggcata	taatacaaa	gcttattaat	ttgactagaa	aatttataaa
	541 attactctga	aattgttaact	aaagtttagaa	agttgatttt	aagaatccaa	acgttaagaa
	601 ttgttaaagg	ctatgattgt	ctttgttctt	ctaccaccca	ccagttgaat	ttcatcatgc
	661 ttaaggccat	gatttttagca	ataccatgtt	ctacacagat	gttcacccaa	ccacatccca
	721 ctcacaacag	ctgcctggaa	gagcagccct	aggcttccac	gtactgcagc	ctccagagag
	781 tatctgaggc	acatgtcagc	aagtcctaag	cctgttagca	tgctgggtgag	ccaagcagtt
	841 tgaaattgag	ctggacctca	ccaagctgct	gtggccatca	acctctgtat	ttgaatcagc
	901 ctacaggcct	cacacacaat	gtgtctgaga	gattcatgct	gattgttatt	gggtatcacc
	961 actggagatc	accagtgtgt	ggctttcaga	gcctcctttc	tggttttggg	agccatgtga
	1021 ttccatcttg	cccgtcagg	ctgaccactt	tatttctttt	tggtcccttt	tgcttcattc
	1081 aagtcagctc	ttctccatcc	taccacaatg	cagtgccctt	cttctctcca	gtgcacctgt
	1141 catatgctct	gattttatctg	agtcactctc	tttctcatct	tgtecccaac	acccacaga
	1201 agtgctttct	tctcccaatt	catectcact	cagtcagctt	tagttcaagt	cctgcctctt
	1261 aaataaacct	ttttggacac	acaaattatc	ttaaaactcc	tgtttcactt	ggttcagtag
	1321 cacatgggtg	aacactcaat	ggtttaactaa	ttcttgggtg	tttaccctat	ctctccaacc
	1381 agattgtcag	ctccttgagg	gcaagagcca	cagtataatt	ccctgtttct	tccacagtgc
	1441 ctaataatac	tgtggaacta	ggttttaata	attttttaat	tgatgtgtgt	atgggcagga
	1501 tggcaaccag	accattgtct	cagagcaggt	gctggctctt	tcctggctac	tccatgtttg
	1561 cttagcctct	gtaacctctt	acttattatc	ttcaggacac	tcactacagg	gaccagggat
	1621 gatgcaacat	ccttgtcttt	ttatgacagg	atgtttgtct	agctttctca	acaataagaa
	1681 gcacgtggta	aaacacttgc	ggatatctct	gactgttttt	aaaaaatata	cagtttaccg
	1741 aaaatcatat	aattcttaca	tgaaggagac	tttatagatc	agccagtgc	caaccttttc
	1801 ccaaccatac	aaaaattctt	tttcccgaag	gaaaagggct	ttctcaataa	gcctcagctt
	1861 tctaagatct	acaaagatag	ccaccgagat	ccttatcgaa	actcatttta	ggcaaatatg
	1921 agtttttattg	tccgtttact	tggttcagag	tttgtattgt	gattatcaat	taccacacca
	1981 tctcccatga	agaaagggaa	cggtgaagta	ctaagcgcta	gaggaagcag	ccaagtcggg
	2041 tagtggaagc	atgattgggtg	cccagtttagc	ctctgcagga	tgtggaaacc	tccttcagag
	2101 ggaggttcag	tgaattgtgt	aggagaggtt	gtctgtggcc	agaattttaaa	cctatactca

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgcctgt ccggtggaga
2221 tcccacccga acgtcttata taatcatgaa actccctagt tccttcattg aacttccttg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca caggttataa
2401 tcatttatca tatatatata tacatgcata cactctcaaa gcaaataatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      HSHUMIG      2545 bp      RNA      PRI      16-NOV-1993
DEFINITION H.sapiens Humig mRNA.
ACCESSION  X72755 S60728
NID        g311375
KEYWORDS   chemokine; cytokine; Humig gene; secreted protein.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2545)
  AUTHORS  Farber, J.M.
  TITLE    Direct Submission
  JOURNAL  Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of
            Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE  2 (bases 1 to 2545)
  AUTHORS  Farber, J.M.
  TITLE    HuMig: a new human member of the chemokine family of cytokines
  JOURNAL  Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
  MEDLINE  93236577
FEATURES   Location/Qualifiers
            source          1..2545
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /germline
                           /dev_stage="child"
                           /tissue_type="leukaemia"
                           /cell_type="monocyte"
                           /cell_line="THP-1"
                           /clone_lib="THP-1/IFN-gamma cDNA"
                           /clone="H-1-3"
            misc_feature    13..19
                           /note="cis-acting element; putative"
            gene            40..417
                           /gene="Humig"
            CDS             40..417
                           /gene="Humig"
                           /codon_start=1
                           /db_xref="PID:g311376"
                           /db_xref="SWISS-PROT:Q07325"

```

/translation="MKKSGVLFLLGIILLVLIGVQGPVVRKGRCSISTNQGTIHLQ

```

SLKDLKQFAPSPSCEKIEIIATLKNQVQTCNLNPDADVKELIKKWEKQVSQKKKQKNG
KKHQKKKVLKVRKSQRSQKKT"

```

```

BASE COUNT      755 a      581 c      457 g      752 t
ORIGIN

```

```

1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aattttcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaactatg tctaaaccca gattcagcag atgtgaaagga actgattaaa
301 aagtggggaga aacagggtcag ccaaaagaaa aagcaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtcc tgaaagtctg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaaag gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccacca ccagttgaat ttcattatgc
661 ttaaggccat gatttttaga ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcaaacag ctgcctggaa gagcagccct aggttccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcttaag cctgttagca tgctgggtgag ccaagcagtt

```

```

841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt ggggtatcacc
961 actggagatc accagtgtgt ggctttcaga gcctcccttc tggctttgga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccctt tgccttcatc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga
1201 agtgcctttc tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt
1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt gggtcagtac
1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctcttgagg gcaagagcca cagtatatct cctgtttctt tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcttggtctc tccatgttgg
1561 ctgacctctg gtaacctctt acctattatc ttcaggacac tcactacagg gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgctc agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagttttaccg
1741 aaaatcatat aatcttacaa tgaaaaggac tttatagatc agccagtgac caaccttttc
1801 ccaaccatac aaaaattcct tttccggaag gaaaagggtc ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta gcaaatatg
1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cggtagagta ctaagcgcta gaggaagcag ccaagtcggg
2041 tagtggaagc atgattgggtg cccagtttagc ctctgcagga tgtggaaacc tccttcagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca
2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtctg ccggtggaga
2221 tcccacccga acgtcttctc taatcatgaa actccctagt tccttcattg aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca cacgttataa
2401 tcatttatca tataatatac tacatgcata cactctcaaa gcaataaatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      A genetic selection for isolating cDNAs encoding secreted
proteins
JOURNAL    Gene 198 (1-2), 289-296 (1997)
MEDLINE    98036061
REFERENCE  2 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES   Location/Qualifiers
            source      1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
blood      mononuclear cells"
            gene        1..995
                        /gene="H174"
            CDS          88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```

/db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"

BASE COUNT 382 a 170 c 194 g 249 t

ORIGIN

```

1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggct
121 gtgatattgt gtgctacagt tgttcaaggc ttccccatgt tcaaaagagg acgctgtctt
181 tgcataggcc ctggggtaaa agcagtgaag gtggcagata ttgagaaagc ctccataatg
241 taccgaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
361 aagaattttt aaaaatatca aaacatatga agtcctggaa aagggcattct gaaaaacctt
421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
481 ttctatggtt ttgtgacttt caacttttgt acagtatatg gaaggatgaa aggtgggtga
541 aaggaccaa aacagaaata cagtcttcct gaatgaatga caatcagaat tccactgccc
601 aaaggagtc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctgggtac
661 catcggagtt tacaagtgcc ttacacgttc ttacttggtg tattatacat tcatgcattt
721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgtgtgta ctatgagaac
781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgttg
841 ttacagtgga gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc

```

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.

ACCESSION AF030514
NID g3219692

KEYWORDS

SOURCE

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;

Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T.,

Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E.,

Sahagan, B.G.

and Neote, K.

TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a

novel

non-ELR CXC chemokine with potent activity on activated T cells

through selective high affinity binding to CXCR3

J. Exp. Med. 187 (12), 2009-2021 (1998)

98290735

REFERENCE 2 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.

TITLE Direct Submission

JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,

Eastern

Point Road, Groton, CT 06340, USA

FEATURES Location/Qualifiers

source 1..1371

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="4"

/cell_type="astrocytes"

sig_peptide 70..132

CDS 70..354

/note="chemokine; I-TAC"

/codon_start=1

/product="interferon stimulated T-cell alpha

chemoattractant precursor"

/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD

IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"

mat_peptide 133..351

/evidence=not_experimental

```

/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT      487 a      228 c      244 g      411 t      1 others
ORIGIN
1   ctccctccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61  aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc ttgtcatagg ccttggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccacag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggttggtt accatcggag tttcaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcacc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcacgggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatagtgtg gtttactgta cttttgtgtt tgatccgttt
1201 gtataaatga tagcaatc ttggacacat ttgaaataca aaatgttttt gtctacaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a
//

```

```

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G. and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
            novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL    J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE    98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL    Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton, CT 06340, USA
FEATURES   Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1
                        /product="interferon stimulated T-cell alpha
                        chemoattractant precursor"
                        /db_xref="PID:g3219693"

```

```

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
IEKASIMYPSNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctcttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt ggtgtctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtg aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac tttctatgg tttgtgtact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttcaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcac ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgtatat tactatctgt ggttacagt gagacattga
841 cattattact ggagtcagc ccttataagt caaaagcatc tatgtgtcgt aaagcatttc
901 tcaaacattt ttctatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggctc taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatgtgtgt gtttactgta cttttgttt tgatccgttt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaa
1261 gaaaaatggt gaaaaataag caaatgtata cctagcaatc acttttactt ttgttaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G. and Neote,K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel non-ELR CXC chemokine with potent activity on activated T cells
through selective high affinity binding to CXCR3
J. Exp. Med. 187 (12), 2009-2021 (1998)
JOURNAL MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD

mat_peptide IEKASIMYPSPNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF
133..351

/evidence=not_experimental

/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN

```

1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgtgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccgaag taacaactgt
241 gacaaaatag aagtgttat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcac ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcatttc
901 tcaaacattt ttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccgggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatttgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatc tttggacacat ttgaaatata aaatgttttt gctaccaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1560)
AUTHORS Matsushima, K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer Institute., Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S., Kobayashi, Y., Lew, W., Appella, E., Kung, H. F., Leonard, E. J. and Oppenheim, J. J.
TITLE Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES
source Location/Qualifiers
1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"


```

CDS             102..401
                /codon_start=1
                /product="MDNCF precursor (AA -27 to 72)"
                /db_xref="PID:g34519"
                /db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF

HPKFIKELRVIESGPHCANTEIIVKLSDBGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide     183..398
                /note="mat. MDNCF (AA 1 - 72)"
BASE COUNT      526 a    247 c    281 g    506 t
ORIGIN
1  ctccataagg cacaactttt cagagacagc agagcacaca agcttctagg acaagagcca
61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
121 tggctctctt ggcagccttc ctgatttctg cagctctgtg tgaagggtgca gttttgcca
181 ggagtgtctaa agaacttaga tgtcagtgcg taaagacata ctccaaacct ttccaccca
241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
301 ttgtaaaagt ttctgatgga agagagctct gtctggacce caaggaatac tgggtgcaga
361 gggttgtgga gaagtttttg aagagggctg agaattcata aaaaaattca ttctctgtgg
421 tatccaagaa tcagtgaaga tgccagtga aactcaagca aatctacttc aacacttcat
481 gtattgtgtg ggtctgttgt agggttgcca gatgcaatac aagattcctg gttaaatttg
541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
601 atgtaaagta ttattttatt gaatctacaa aaaacaacaa ataattttta aatataagga
661 ttttcctaga tattgcacgg gagaatatac aaatagcaaa attgggccaa gggccaagag
721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaattgtat atttgaagca
781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
841 ggattttttt ctgttaaatac tggcaaccct agtctgtctg ccaggatcca caagtccttg
901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
961 acctcacagt gatgtgtgta ggacatgtgg aagcacttta agttttttca tcataacata
1021 aattattttc aagtgttaact tattaacctt tttattattt atgtatttat ttaagcatca
1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
1141 atgttatagt aaattttatt ttttttagat attaaatgat gttttattag ataaatttca
1201 atcagggttt ttagattaaa caaacaacaa attgggtacc cagttaaatt ttcatttcag
1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtggt ggtagtgtcg
1381 tgttgaaata cggaataatg agttagaact attaaaacag ccaaaactcc acagtcaata
1441 ttagttaatt cttgctggtt gaaactgttt tattatgtac aaatagattc ttataatatt
1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttta aaaaaaccgg

```

//

```

LOCUS      HSINFGFR      1172 bp      RNA      PRI      21-MAR-1995
DEFINITION Human mRNA for gamma-interferon inducible early response gene
(with      homology to platelet proteins).
ACCESSION  X02530 M17752
NID        g33917
KEYWORDS   interferon response; signal peptide.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1172)
AUTHORS    Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE      Gamma-interferon transcriptionally regulates an early-response
gene
            containing homology to platelet proteins
            Nature 315 (6021), 672-676 (1985)
JOURNAL    85240552
MEDLINE    2 (bases 1 to 1172)
REFERENCE  Luster,A.D.
AUTHORS    Direct Submission
TITLE      Submitted (29-JUL-1986) to the EMBL/GenBank/DDBJ databases
COMMENT    Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES   Location/Qualifiers
            source          1..1172
                        /organism="Homo sapiens"
                        /strain="(U 937 histiocytic lymphoma cell line)"
                        /db_xref="taxon:9606"
            misc_RNA        1
                        /note="cap site"

```

sig_peptide 67..129
 /note="pot. signal peptide (aa-21 to -1)"
 CDS 67..363
 /note="early response precursor polypeptide (aa-21 to 77)"
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTALICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGKRLNPESKAIKNLLKAVSKEMSKRSP"

mat_peptide 130..360
 /note="mature early response polypeptide (aa 1-77)"
 old_sequence 1138..1141
 /note="ugaa was uga in [1]"
 /citation=[1]
 old_sequence 1146..1148
 /note="caa was ca in [1]"
 /citation=[1]
 misc_feature 1155..1160
 /note="pot. polyA signal"
 polyA_site 1172
 /note="polyA site"

BASE COUNT 384 a 231 c 208 g 349 t
 ORIGIN

```

1 gagacattcc tcaattgctt agacatatcc tgagcctaca gcagaggaac ctccagtctc
61 agcaccatga atcaaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatacagcat tagtaatcaa
181 cctgtttaatc caaggctctt agaaaaactt gaaattattc ctgcaagcca attttgtcca
241 cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtgtgca
481 gttacactaa aaggtgacca atgatggta ccaaatcagc tgctactact cctgtaggaa
541 gggtaatggt catcatccta agctattcag taataactct accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtgga tgctctgacc ctgcttcaaa tatttccctc
661 acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc
721 tcagaatctc aaataactaa aaggtatgca atcaaatctg ctttttaaaag aatgctcttt
781 acttcatgga cttccactgc catctcccca aggggcccaa attctttcag tggctaccta
841 catacaattc caaacacata caggaaggta gaaatatctg aaaatgtatg tgtaagtatt
901 cttatttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatatatt
961 tttcagtgtg catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
1081 ttttcaataa aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
1141 aagatcaaaa ggtaataaaa gtaattataa ct

```

//

LOCUS SYNRP4A 225 bp DNA SYN 15-JUN-1989
 DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
 ACCESSION M20901
 NID g209285
 KEYWORDS platelet factor; platelet factor 4.
 SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
 ORGANISM artificial sequence.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Barone,A.D., Ghrayeb,J., Hammerling,U., Zucker,M.B. and Thorbecke,G.J.
 TITLE The expression in Escherichia coli of recombinant human platelet factor 4, a protein with immunoregulatory activity
 JOURNAL J. Biol. Chem. 263, 8710-8715 (1988)
 MEDLINE 88243725
 FEATURES
 source Location/Qualifiers
 1..225
 /organism="artificial sequence"
 /db_xref="taxon:29278"
 CDS
 <1..>225
 /note="recombinant platelet factor 4"
 /codon_start=2

/transl_table=11
/db_xref="PID:g209286"

/translation="ASMEAEDGDLQCLCVKTTTSQVRPRHITSLEVIKAGPHCPTAQL
IATLKDGRKICLDLQAPLYKKI IKKLL ESGS"

BASE COUNT 59 a 59 c 51 g 56 t
ORIGIN HindIII site.
1 agcttctatg gaagctgaag aagacgggtga cctgcagtgc ctgtgcgtta aaactacttc
61 tcagggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggte cgcattgccc
121 gactgctcag ctgacgccta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggc
181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc

//

LOCUS HUMGRO 1050 bp mRNA PRI 11-JUN-1993
DEFINITION Human gro (growth regulated) gene.
ACCESSION J03561
NID g183622
KEYWORDS gro gene; tumor cell.
SOURCE Human bladder tumor cell (T24) cDNA to mRNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1050)
AUTHORS Anisowicz, A., Bardwell, L. and Sager, R.
TITLE Constitutive overexpression of a growth-regulated gene in
transformed Chinese hamster and human cells
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
MEDLINE 88041072
COMMENT Draft entry and computer-readable sequence kindly submitted by
R. Sager (20-NOV-1987).
FEATURES
source Location/Qualifiers
1..1050
/organism="Homo sapiens"
/db_xref="taxon:9606"
sig_peptide 54..140
/note="signal peptide (put.); putative"
CDS 54..377
/note="gro protein"
/codon_start=1
/db_xref="PID:g306806"

/translation="MARAALSAAPSNPRLLRVALLLLLVAAGRRRAAGASVATELRQC

CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPA SPIVKKIIEKMLN

SDKSN"
mat_peptide 141..374
/note="gro mature protein (put.); putative"

BASE COUNT 270 a 246 c 239 g 295 t
ORIGIN 52 bp upstream of NcoI site.
1 ctcgccagct cttccgctcc tctcacagcc gccagaccgc cctgctgagc cccatggccc
61 gcgctgctct ctcgcgcgcc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
121 tgctcctggt agccgctggc cggcgcgagc caggagcgct cgtggccact gaactgcgct
181 gccagtgttt gcagaccctg cagggaattc accccaagaa catccaaagt gtgaacgtga
241 agtcccccg accccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
301 aagcttgctt caatcctgca tcccccatag ttaagaaaat catcgaaaag atgctgaaca
361 gtgacaaaat caactgacca gaaggaggga ggaagctcac tgggtgctgt tcctgaagga
421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
481 ttgtgcctaa tgtgtttgag catcgcttag gagaagctt ctatttattt atttattcat
541 tagttttgaa gattctatgt taatatTTTA ggtgtaaaat aattaaagggt atgattaact
601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgttctcc agtcattatg
721 ttaatatTTTc tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
841 actgttttaga tgaatgtcag ttgttatTTA ttgaaatgat ttcacagtgt gtggtcaaca
901 tttctcatgt tgaaactTTA agaactaaaa tgttctaaat atcccttgga cattttatgt
961 ctttcttgta aggcatactg ccttgTTTaa tggtagtttt acagtgtttc tggcctagaa
1021 caaaggggct taattattga tgttttcgga

//

LOCUS HUMGROB5 1110 bp mRNA PRI 07-MAR-1995
DEFINITION Human cytokine (GRO-beta) mRNA, complete cds.

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES
 source Location/Qualifiers
 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLRLRVALLLLLVAASRRAGAPLATELRQC

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNQKACLNPASPMVKKIIIEKMLK
 NGKSN"

BASE COUNT	300 a	247 c	247 g	316 t
ORIGIN				
1	gacagagccc	gggccacgga	gctccttgcc	agctctcctc
61	gectgctgag	ccccatggcc	cgcgccacgc	tctccgcgcg
121	tgccgggtggc	gctgctgctc	ctgctcctgg	tgccgcgcag
181	ccctggccac	tgaactgcgc	tgccagtgt	tcagaccct
241	acatccaaag	tgtgaagggtg	aagtcctccg	gacccactg
301	ccacactcaa	gaatgggcag	aaagcttgct	tcaacccgcg
361	tcacgaaaaa	gatgctgaaa	aatggcaaat	ccaactgacc
421	ttggtggctg	ttcctgaagg	aggccctgcc	ttacaggaac
481	agctgcagag	gccacctggc	ttgcgcctaa	tgtgtttgag
541	tatttattta	tttatttatt	tattgtttg	ttttagaaga
601	tgtaaaaata	ggttatgatt	gaatctactt	gcacactctc
661	tttaggtcaa	acccaagtta	gttcaatcct	gattcatatt
721	tgcagatatt	ctctagtcat	ttgttaatat	ttcttcgtga
781	actgtgatag	aggctgagga	atccaaagaa	atggccagta
841	aaatgtatgt	gtgtctatgt	tgttaactgt	aagatgaatg
901	tgatttcaca	gtgtgtgggc	aacatttctc	atgttggaagc
961	aaatatccct	tggcatttta	tgtctttctt	gtaagatact
1021	tcagtggttt	ccctctgtgt	tagagcagag	aggtttcgat
1081	agaacaggaa	aataaaatat	ttaaaaaatat	

LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

TITLE Lee,S.W., Smith,T., Martin,G., Ralph,P. and Sager,R.
 cytokine Identification of three related human GRO genes encoding
 functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLLRVALLLLLLVGSRRAGASVVTELRCQC

LQTLQGIHLKNIQSVNVRSFPGPHCAQTEVIATLKNGKKACLNPPASPMVQKIIIEKILNK
GSTN"

BASE COUNT 281 a 237 c 239 g 305 t 2 others
ORIGIN

```

1 cacagccggg tcgcaggcac etccccngcc agctctcccg cattctgcac agcttccccg
61 cgcgtctgct gagccccatg gcccaagcca cgctctccgc cgccccagc aatccccggc
121 tcctgcegggt ggcgctgctg ctctgtctcc tgggtgggcag ccggcgcgca gcaggagcgt
181 ccgtgggtcac tgaactgctg tgccagtgtc tgcagacact gcagggaatt cacctcaaga
241 acatccaaag tgggaatgta aggtcccccg gaccccaactg cgcccaaacc gaagtcatag
301 ccacactcaa gaatgggaag aaagcttgtc tcaaccccg atcccccatg gttcagaaaa
361 tcactcgaaaa gatactgaac aaggggagca ccaactgaca ggagagaagt aagaagctta
421 tcagcgtatc attgacactt cctgcagggt ggtccctgcc cttaccagag ctgaaaatga
481 aaaagagaac agcagctttc tagggacagc tggaaaggga cttaatgtgt ttgactatgt
541 cttacgaggg ttctacttat ttatgtatgt atttttgaaa gcttgtatgt taatatttta
601 catgctgtta tttaaagatg tgagtgtgtt tcatcaaaaca tagctcagtc ctgattatgt
661 aattggaata tgatgggttt taaatgtgtc attaaactaa tatttagtgg gagaccataa
721 tgtgtcagcc accttgataa atgacagggt ggggaactgg agggtnnggg gattgaaatg
781 caagcaatta gtggatcact gttagggtaa gggaatgtat gtacacatct atttttata
841 cttttttttt taaaaaagaa tgtcagttgt tattttattca aattatctca cattatgtgt
901 tcaacatttt tatgctgaag ttcccttag acattttatg tctgtctgt agggcataat
961 gccttgttta atgtccattc tgcagcgttt ctctttccct tggaaaagag aatttatcat
1021 tactgttaca ttgtacaaa tgacatgata ataaaagttt tatg

```

//

LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein;
 thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger,R.H., Wicki,A.N., Walz,A., Kieffer,N. and Clemetson,K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 from a human platelet-derived lambda gt11 expression library
 JOURNAL Blood 73 (6), 1498-1503 (1989)
 MEDLINE 89229374
 FEATURES Location/Qualifiers
 source 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gt11"
/map="4p13-q21"
gene 67..453
sig_peptide 67..168
CDS 67..453
/feature="PPBP"
/feature="G00-127-391"
/feature="PPBP"
/codon_start=1
/db_xref="GDB:G00-127-391"
/product="connective tissue activating peptide III"
/db_xref="PID:g181176"

/translation="MSLRDTPSCNSARPLHALQVLLLLLLLLTALASSTKGQTKRN
LAKGKEESLSDSLYAE LRMCIKTTS GIHPKNIQSLEVIGKGTCHNQVEVIATLKDGR
mat_peptide KICLDPDAPRIKKIVQKKLAGDESAD"
196..450
/feature="PPBP"
/feature="G00-127-391"
/product="connective tissue activating peptide III"
mat_peptide 208..450
/feature="PPBP"
/feature="G00-127-391"
/product="beta-thromboglobulin"
polyA_site 673
/feature="PPBP"
/feature="G00-127-391"

BASE COUNT 202 a 149 c 139 g 183 t
ORIGIN
1 gggcaactca ccctcactca gaggtcttct ggttctggaa acaactctag ctcagccttc
61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accacttcat
121 gccttgacag tgctgtctgt tctgtcattg ctgctgactg ctctggcttc ctccacaaa
181 ggacaaacta agagaaactt ggcgaaaggg aaagaggaaa gtctagacag tgacttgtat
241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcattccaa aaacatccaa
301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
361 aaggatggga ggaatatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
421 aaaaaattgg caggtgatga atctgctgat taattgttc tgttctgcc aaacttcttt
481 aactcccagg aagggttagaa tttgaaacc ttgattttct agagttctca tttattcagg
541 atacctattc ttactgtatt aaaatttggga tatgtgttct attctgtctc aaaaatcaca
601 ttttattctg agaagggttg ttaaaagatg gcagaaagaa gatgaaaata aataagcctg
661 gtttcaaccc tct

//

LOCUS HUMENA78A 2177 bp DNA PRI 31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
complete cds.
ACCESSION L37036 Z46254
NID g607030
KEYWORDS ENA-78 gene; homologue; neutrophil-activating factor;
neutrophil-activating peptide 78.
SOURCE Homo sapiens DNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2177)
AUTHORS Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
Strieter,R.M.
TITLE Structure and neutrophil-activating properties of a novel
inflammatory peptide (ENA-78) with homology to interleukin 8
JOURNAL J. Exp. Med. 174 (6), 1355-1362 (1991)
MEDLINE 92078844
REFERENCE 2 (bases 1 to 2177)
AUTHORS Walz,A.

```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher
 Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett, M.S., Schmitt, I., Riess, O. and Walz, A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791

FEATURES
 Location/Qualifiers
 source 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et
 al."
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

/translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL

RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNKKEICLDPEAPFLKKV

intron IQKILDGGNKEN"
 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..1747
 /gene="ENA-78"
 /number=4

BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN

```

1  gaattctcag taagcggact taccaaaagta ggtgatctgt aggggaggtta acaaaattca
61  gtggctcctt caggccactg acttcaagtg gcaagagaca agggctctctt gttatcatgt
121 tatcttggct tccaaagctg gttgaagtc agagattcat aaagtcattc aagaaacctt
181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
301 caaatcaagg ctctgtttac tttggttcca ccttttctct ctagaaggag aggaggagca
361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgtctt ggcacaggcc
421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctctctctgg
541 ccaccctccc caccagttcc cattgtcttg cccccctccc ccaacctctt ctttccacac
601 tgccccatga gtccagggaa tttccccagc atcccaaagc ttgagttctt tgtcagtggt
661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggat
```

```

721 cctccaatct tcgctcctcc aatctccgct cctccacca gttcaggaac cgcgcaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcggccc gtgtccccgg
841 tccttcgagc tccttggtgc cgctgttggt gctgctgctg ctgctgacgc agccagggcc
901 catcgccagc ggtgagagcg catggcgcg cggacgcact cgcactcggg cacagaggtg
961 catcccagcc tctgcggggt cgctgcgttc cagggaaact tcccagcaac ctgccctata
1021 aaggggtgtct ctctttcttc cccagctggt cctgccgctg ctgtgttgag agagctgcgt
1081 tgcgtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
1141 ttcgccatag gccacagtg ctccaagggt gaagtgggtg aagtctctgt ctgctgtgtc
1201 cgctgtgacc ttggcaagag agaaatccc cagcctgggt cttcaacctt gggtatctcat
1261 gagtgtatct tctttttctt tcttccagag cctccctgaa gaacgggaag gaaatttgtc
1321 ttgatccaga agcccctttt ctaaagaaaag tcatccagaa aattttggac gggactttgt
1381 cactttgatc tttgtggttt ctaaactctga tctagggaga ccatagactt cacaaggtct
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgaatt
1501 gggaaagtgt ttctggattg tcttgggaaa atataccaat cttacatgta attacttgag
1561 caattacaca cagcttgatc ctaagtattg ttttttgggt acccattgct tttattgatt
1621 ttgtattctt ccttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
1681 aaaggaggtg gaaaaatggt taaactaata taacattttt ctcaacagtg gaaacaagga
1741 aaactgatta agagaaatga gcacgcattg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggaggt ctctgaaccc aggggaagaca agaaggaaaag attttgttgt tgtttgttta
1861 tttgttttct cagttagttg ctttcttcct ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaataga gtgttttaga tagtacctct
1981 gctatttgct gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccaggaat cactggctgt taatctttca aagtgtcttg aattgtaggt gactattata
2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

```

LOCUS       HSGCP2           254 bp      RNA           PRI           04-MAR-1997
DEFINITION   H.sapiens mRNA for granulocyte chemotactic protein.
ACCESSION   Y08770
NID         g1769436
KEYWORDS     cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte
             chemotactic protein.
SOURCE      human.
ORGANISM     Homo sapiens
             Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
             Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 254)
AUTHORS     Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A.,
Wuyts,A.,
             Opdenakker,G., Van Damme,J. and Billiau,A.
TITLE       Cloning, bacterial expression and biological characterization
of          recombinant human granulocyte chemotactic protein-2 and
             differential expression of granulocyte chemotactic protein-2
and         epithelial cell-derived neutrophil activating peptide-78 mRNAs
JOURNAL     Eur. J. Biochem. 243 (3), 762-769 (1997)
MEDLINE     97210779
REFERENCE   2 (bases 1 to 254)
AUTHORS     Froyen,G.F.V.
TITLE       Direct Submission
JOURNAL     Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute,
University  of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
FEATURES
  source     Location/Qualifiers
             1..254
             /organism="Homo sapiens"
             /db_xref="taxon:9606"
             /haplotype="diploid"
             /tissue_type="embryonic"
             /rearranged
             /cell_type="fibroblast"
             /cell_line="E6SM (embryonic strain - skin and muscle)"
  gene       1..254
             /gene="GCP-2"
  exon       <1..131
             /gene="GCP-2"
             /number=2
  CDS        <1..234
             /gene="GCP-2"

```



```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
              ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
      exon      132..215
                /gene="GCP-2"
                /number=3
      exon      216..254
                /gene="GCP-2"
                /number=4
      3'UTR      235..254
                /gene="GCP-2"

BASE COUNT      66 a      64 c      70 g      54 t
ORIGIN
      1 ggtcctgtct ctgctgtgct cacggagctg cgttgcaactt gtttacgcgt tacgctgaga
      61 gtaaacccca aaacgattgg taaactgcag gtgttccccc caggcccgcg gtgctccaag
      121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggaccc ggaagccctt
      181 tttctaaaga aagtcattca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
      241 gtcgacgcgg ccgc

//

LOCUS      D63789      5669 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1beta precursor, complete cds.
ACCESSION  D63789
NID        g1754608
KEYWORDS   SCM-1beta; SCM-1beta precursor.
SOURCE      Homo sapiens placenta DNA, clone:hg44.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1.
JOURNAL    FEBS Lett. 360 (2), 155-159 (1995)
MEDLINE    95180438
REFERENCE  2 (sites)
AUTHORS    Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
            and Yoshie,O.
TITLE      Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
JOURNAL    FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE    97002294
REFERENCE  3 (bases 1 to 5669)
AUTHORS    Yoshida,T.
JOURNAL    Unpublished (1995)
REFERENCE  4 (bases 1 to 5669)
AUTHORS    Yoshida,T.
TITLE      Direct Submission
JOURNAL    Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya
            Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,
            Settsu, Osaka 566, Japan (E-
            mail:teyoshid@fl.lab.shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
FEATURES
      source      Location/Qualifiers
                  1..5669
                  /organism="Homo sapiens"
                  /db_xref="taxon:9606"
                  /chromosome="1"
                  /clone="hg44"
                  /map="1q23"
                  /tissue_type="placenta"
      TATA_signal  2154..2158
      exon         2197..2278

```

```

/number=1
prim_transcript 2197..5349
gene 2218..5230
/ gene="SCM-1beta"
CDS join(2218..2278,4075..4189,5062..5230)
/ gene="SCM-1beta"
/ codon_start=1
/ product="SCM-1beta precursor"
/ db_xref="PID:d1010504"
/ db_xref="PID:g1754609"

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRCVSLTTQRLPVS
IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
intron 2279..4074
/ gene="SCM-1beta"
/ number=1
exon 4075..4189
/ gene="SCM-1beta"
/ number=2
mat_peptide join(4077..4189,5062..5227)
/ gene="SCM-1beta"
intron 4190..5061
/ gene="SCM-1beta"
/ number=2
exon 5062..5349
/ number=3
BASE COUNT 1702 a 1058 c 1248 g 1661 t
ORIGIN

```

```

1 ggatccagga ggataacaag ggaatctcct actctcaaa agtctgccat ctagtgggag
61 acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
121 acagaacaaa gttctaagag agcataaagg ggtggcacia ctttaatttta tcaaaaaaat
181 tcaggaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
241 gtattccagt taaaggaaac atgtgaggag cataaaagag gctggcccat tgggttggtc
301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatgggtga aggtgagctc
361 gaaaggaaa cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaat
421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaat gccatgatta
481 gattgaggct ttacagtgat taccctggca aagctgcaga gaacagactg agaggaggcc
541 ctggtctggg taaccagtta gtccactgta atttgcctaa catttgagca gtgtggggag
601 aaaggaggac acatctcaaa ggactaccta gaaggtatac ttagtccagt ttggttgaga
661 atgacatgta ggtggatagc aatgagtcta agatgatccc tatatatcag tatttgaaa
721 ttgatggaa gagaacacat tgctccatgc taaggactaa tatgaggaga agcagtttga
781 atagaagatg tgtccagtgt tcaaggagtg attgtgcagt aaggtagaga tcattaaaga
841 gccagtttga agtttagaat gaagctctggg tgaaaaatca aatgcgatta gtgggaagtc
901 tcttagaggt taacctatac tttttatgaa aacataggaa tttattttca tattccctaa
961 tagcaaaagg cctttaacta cacatatatt taataaatat attttataga tacctatgta
1021 aaataaagaa caaccaccac acaacaaact cagtggcaga aaagttccag tgcaatcagt
1081 atatttaaat tctactgggg gtattgcaaa tcaaatttac attttgggag actatatggc
1141 aatatataat aagagctata aagatgatca tatcattttt cccagtaate ctactcctgg
1201 ttattaaagg gaagtaattc agtgtatatt aatgaaatcg accttatagt tctgatcttt
1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
1321 tatgaaggct aaaaaaatgg gaagatattt aaattgggtg taaaacagca tttaaaatta
1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
1441 aaactgtcag atggtaaagt tataattttt tttctttttt aatttgaaat aaattggtaa
1501 cagcacagct tttcaaaagc ttctataaat gtgtatgtta agtttgtaata aagcaaacac
1561 atgcatgtaa gacatgctta aacagttatt taattgtttc ttgggtacct ggggagatgg
1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaatgagaa ccaagaaagc
1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gagtcaaaag
1741 gtggcatcag ggactcatga tccatgggtg tggaagcctc atgtcacact ggatgtcaca
1801 agagggtgga tggaaacacag tgaccacccc acctcatttc ctttacagct tccgtggggg
1861 catggcaggt gaacagcctt caggcatgtc tacgttgga gatctgaatt caggctgggtg
1921 acaggagaca acacaaccac gttttctttt atgcattgat ttggtttaat tgacacatta
1981 ccacagaca aagggttaaa ggccacaagg cgatagggtta gtatgaacag ggaaaggagc
2041 attttttttt ttttaagaaa ataaaagcat cagtattgca aagactttcc atgatcctat
2101 acccacctcg aaagccccct ctcaccacag gaagtgcact gaccattgga ggcataaaag
2161 agatcctcaa agagcccgat cctcactctc cctgcacagc tcagcgggag ctcagccatg
2221 agactttctc tcttgccctt ccttgccatc tgctctctca ctgcatacat tgtggaaggt
2281 aagtggagaa gctgtctgtg agataaagaa tagggaggca aggcaggtgg gcacacattt
2341 tgggtttgac tcgggttttg actggactaa actgctgtct ccaggggagc cttaaacttc
2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaca

```

```

2461 gggagaattt gattagatc tgggctccta cttttcctaa ttgggtaatt tcaggtaaat
2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaagatta aataaaatatt atgggttatt taataacatc agatttcctt
2641 acaagcagta attttttgat taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtagggt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagtct
2761 agttacaata tggggatgca ccagaggatg tatgttctgg agcaaatcaa tgttttcaat
2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagtcttgcc
2881 ttctctcccc ttgataatgc aataagggac ccccatTTta ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttggt
3001 ttccagcaag gtggtgatga tgttaacccc tgctcaaaga acaggtgatt tcttagtggg
3061 gacaacccct ttgctagcag ctttcttctc agcctgggcc aacagtctct gcttcttctc
3121 ttgctttgtc tctggtcagt acttgtggat cagcttaagt ggctgagtag ctggttgagg
3181 gtctaaggct tgggtgaact ggttaatggc agaaggcatt ttcagctgct tatagaggat
3241 agctctttgc agctggaacc agatatagcg gggccatttc acaaagcagt ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct ttctcacac
3361 agcggtttca tcactttctt agcctcctgc ttcctcacga cggcagggac tgggccacct
3421 tctttctctt ggccttcttt cttttcagca tcttaggcag ctgacagaga gggaaatttg
3481 accatttaaa aagggggaaca cttttattta ctcagtcaaa agcatgtctc ctccctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtag
3601 tgtaacatgt tgcactatct gaaatgatct tttctgtttg cctgtctgct gcctggctcc
3661 ctcatgagaa gatagtctct atgaaaacag ggataatgtc tgtcttaata aaacatgttg
3721 gacacaacag gcaccattgt ataaatgaat gaatgcgtgt cactggggca tttgctagcc
3781 gtcccaaatg tctaagtga aatatacaca gagacgggat aacatcttgt tattttctct
3841 cagcatgaaa ttcttgaaac aattctgttg attgagtttt taaattagtc aaatatttac
3901 taagaatctg tgacgggcaa gagattcggg atgcctatca gtctctctct ccccaaaaaa
3961 gcaaatggcc ttatatctct acaacattct cagagtaatt taacagacga ttgttctctg
4021 gatctgggta attgtcttat ttttaattgt ctggtgtttt tttttctca tcagggtgat
4081 ggagtgaagt ctcacatagg aggacctgtg tgagcctcac taccagcga tctccctca
4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatt tgagtctgcc
4201 tcctcagaag ttgggctggg tgggtacctt gaggtataga aatacactct atagaaatgc
4261 tgccatcttc aggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaagaaa aatagaagtc ctctcttatt tgtcttagtg gaagagtctg
4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctggctca ggtcagggtt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatac
4561 tttatcagtt gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcattttt agaagtaata actcttccca atacatattg caagctttgc
4681 tctaaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 tttgaaaagg aagagggttat ataataatgg aactagatgg cctcaaatgt ctttttggtt
4801 caacatttgg tgacatggat gagaaaagga gcctgtgta tttggtgaac aaaggggctg
4861 gatactactt gcagatattt ctcttttatg ttaaaataga tggcagaaga aggggtctca
4921 tttatgatct catggctctg aaagactatt tcttgacgta atttctgcac aagatctctt
4981 catgtctgac ctgatcttaa ctctgacccc tgaggctttg agaacgtggc taacttcatc
5041 tgcctttctc ttgcgttaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
5101 acaagccacg tgggtgagag acgtgggtcag gagcatggac aggaaatcca acaccagaaa
5161 taacatgatc cagaccaagc caacaggaaac ccagcaatcg accaatacag ctgtgacctt
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcaattta
5281 caccctcatg gactgagatt atactcacct tttatgaaag cactgcataa ataaaaattt
5341 tcctttgtat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 ttattttatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtagtgtg
5461 tcattgttgt ttgatttctg accttgtacc tctctttgat ggtaaccata atggaagaga
5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
5581 aatgggtctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

```

LOCUS      D63790      5660 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-lalpha precursor, complete cds.
ACCESSION  D63790
NID        g1754610
KEYWORDS   SCM-lalpha precursor; SCM-1 alpha.
SOURCE     Homo sapiens placenta DNA, clone:hg40.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL     FEBS Lett. 360 (2), 155-159 (1995)

```

MEDLINE 95180438
 REFERENCE 2 (sites)
 AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
 Yaoi,T.
 and Yoshie,O.
 TITLE Structure and expression of two highly related genes encoding
 SCM-1/human lymphotactin
 JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
 MEDLINE 97002294
 REFERENCE 3 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 JOURNAL Unpublished (1995)
 REFERENCE 4 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 TITLE Direct Submission
 JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
 Tetsuya

Yoshida, Shionogi Institute for Medical Science; 2-5-1,
 Mishima,
 Settsu, Osaka 566, Japan (E-
 mail:teyoshid@fl.lab.shionogi.co.jp,
 Tel:06-382-2612, Fax:06-382-2598)

FEATURES Location/Qualifiers
 source 1..5660
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="1"
 /clone="hg40"
 /map="1q23"
 /tissue_type="placenta"
 TATA_signal 640..644
 exon 683..764
 /number=1
 prim_transcript 683..5340
 CDS join(704..764,4064..4178,5053..5221)
 /codon_start=1
 /product="SCM-1alpha precursor"
 /db_xref="PID:d1010505"
 /db_xref="PID:g1754611"

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR

IKTYTITEGSLPAVIFITKRGLKVCADPQATWVRDVVRSMRDKSNTRNNMIQTKPTGT

QSTNTAVTLTG"
 intron 765..4063
 /number=1
 exon 4064..4178
 /number=2
 mat_peptide join(4066..4178,5053..5218)
 /note="SCM-1alpha mature peptide"
 intron 4179..5052
 /number=2
 exon 5053..5340
 /number=3

BASE COUNT 1623 a 1139 c 1175 g 1723 t
 ORIGIN

```

1 aagcttctat aaatgtgtat gtttaagttgt aataaagcaa acacatgcat gtagacatgc
61 ttaaacagtt atttaattgt ttcttgggta cctggggaga tgggggtgaag aaaggggggt
121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
181 agtgtggcag cagctctctt cccctcctga gagagtcaaa ggggtggcatc agggactcat
241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
301 agtgaccacc ccacctcatt tcttttacag cttccgtggt gggccatggc agtgaacacc
361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
541 agaaaaataa aagcatcagt attgcaaaga ctttccatga tcctacaccc acctcgaaag
601 cccctctca ccacaggaag tgcactgacc actggaggca taaaagaggt cctcaaaagag
661 cccgatectc actctccttg cacagctcag caggacctca gccatgagac ttctcatcct
721 ggccctcctt ggcattctgt ctctcactgc atacattgtg gaaggttaagt ggagaagctg
781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg tttgactcag
841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa

```

901 ggaatgatga ttttgactgt agaggggttc gtaaacttcc aaaacagggg gaatttgatt
961 agtatctggg ctctactttt tcttaattgg gtaatttcag gtaaatccct taaccactca
1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
1081 gattaaataa atattatggt ttatttaata acatcagatt tccttacaag cagtaatttt
1141 ttgattaatg ttagctatgg attagagggt atgattataa atgcatttgt aggttttggc
1201 catttaatat atagtttgat aaattatcaa aatcttagag agttcagtta cgtatgtggg
1261 atgcaccatt ggaagtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
1321 aaatgactgg aagttcaaac ctctcatgtcc agaaaaatcaa tattaccttc aagtcagtgg
1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaattttct gtttttgtaa
1441 gagaacatac aataataact actaccaaag agatcagcac cttatacaca gttcaataaa
1501 cctgcaagac acatccaggt aagattcaga tataccgagc cttactctga gcattcagta
1561 ggtattttct aaggattgat ttttctatg actggagggt aatctgtcga cttatttgtg
1621 ttctagttag taggcttatt acttagacta tgatattata acttaataat ggggtcccaa
1681 ggggttccat gaataaaggt ggctaagctt ggaagtcctt gaaattatgg ataaaaaa
1741 aaaatactga tgaacacaaa gagtttgatt actacattag gccacatgtt gctactggc
1801 tggcattttg ctgagacaat gggcatacca tttgaggagg actcagatct gagtagggga
1861 aaggagctct ataagtccca ctgggtctta gcttcttaca tacaaaaatg agggaaaacg
1921 gtctctgtct ttgcaacctg atggaagggt atatttttaa aaataacaca
1981 gacactcaaa cattgctgac aataaggaaa aggtcttctg gtttcaagca taacaggatt
2041 ccctgagctc taggagctca cttcagatac ttcacagaga gaaatattgt ttcttaata
2101 tgagagaaac agagaaaaaa cccagatttt tctcttttca ttggctacag aaacaattca
2161 ccactaaaaa taaattggca aaggtagagg atagcaatgt gcagactggc attgagagt
2221 aagaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt ggttacttta
2341 gatgcttttt agctgtctat ttccttggga agcaaaagac agtgtctaca gctaaggaga
2401 aaatcagcac ttagaaactt ggattagatt tcacccaacc cttaaacagta ttaattctcc
2461 caagtatttt ttctctatgc aatgtttttt tgattctcta cacttaatat tttaattctt
2521 ttgggcccatt actattgggg atgcataatt aagggctgac ttctttttat atatatctta
2581 ccttttacca tttattaatt ttttgagag tttttattat ttttatgtac agaaaaatca
2641 acagtgtaca ttttaaccag tttagtggca agttctctct cctttgtcat ttccagcttg
2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
2761 taatttgtcc tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
2821 tgtgtgaagg ccacagtggt gcttctctgt gactggatgt ccagctcttg ccttcttacc
2881 ccttgataat gcattaaagg acccccatt ttaggcacaca ggacagacag aaggttaacc
2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
3001 tgggtgatag gttaaccctc gctcaaaaga cagggtgatt cctagtgggg acaaccctt
3061 tgctagcagc tttcttctca gcttgggcca acagctctct gcttttctct tgccttctct
3121 gctgtcagta cttgtggatc agcttaagtgt gctgagttag tgtttggggg tctaaggctt
3181 ggggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
3241 gctggaacca gatatagcgg ggccatttca caaagcagcg gaggtccctt ttgggctgga
3301 tgtcctgtcc aatgctgtcc taagaaaact cttaggcctt ttctcacaca gcggtttcat
3361 cactttctta gctcctgtct tcttcacgac ggcagggtct ggggccattt tcttctctt
3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttt accattttaa
3481 aaggagaaca cctttattta gctctgcaaa agcatgcttc cttccctcac tgaatgttgc
3541 cttgcctaga gtactcttca cgcattactc tgtcttctca ctatggtact gtaacatgtt
3601 gcactatttg aaatgatctt ttctgtttgc ctgtctgtct cctggctctt tcatgagaga
3661 gatagtctct atgaaaacag gagtaatgtc tgcttagtaa aacatgtggg acacaacagg
3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
3781 ctaagtgaat atatacacag agacgggata acatcttgtt attttctctc agcatgaaat
3841 tcttgaacaa attctgttga ttgagttttt aaattagtca aatatttgtt aagaatctgt
3901 gacgggcaag agattcggga tgccatcag tctctctctc ccccaaaaag caaatggcct
3961 taaattctca caacattctc agagtaattt aacagatgat tgttctgtg atctggataa
4021 ttgctttatt ttttaattgtc tgttgttttt ttttctctac cagggttagg gtagtaagtc
4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tgcgggttag cagaatcaag
4141 acctacacca tcacggaagg ctcttgaga gcagtaatgt gactctgctt cctcagaagt
4201 tgtgtctggg gggatcttag aagtatagaa atacactctg tagaaatgct gccgtctca
4261 ggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagtttctc
4321 ttatcaatca tgtctttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
4381 caaagaaaga atagaagtcc tctctatttt agcttagtgg aagagtctgt tgaatactgt
4441 gcacagctct gagacctggg tttagagatg actgggcccgt gtcagggttt cctgcaagc
4501 ctcaactggg ttggggggtc tttaggggtga gtcaggcaga gtccatact tttatcagtt
4561 gccatatttc aagaaaatga gtaaatgcac aaactacatg gtcccttctt ctaccagaat
4621 ctcatatttt gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaaa
4681 tgaaaatgta aaaatcactt ttatttttaa aaataagatg aatattttta attttgaaaa
4741 ggaagagggt atgtaataat ggaactagtt ggcctcaaaag tctttttgtt acaacatttg
4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggatactact
4861 tgcagatatt actcctttat gttaaaaatg atggcagaag aagggtactc atttatgac
4921 tcatggctct gaaagactat ttcttgagc aatttctgca caagatctct tcatgtctgc
4981 cctgatctta actcctgacc ctgaggcttt gagaatgtgg ctaactctgt ctgtcttttc
5041 cttgcgttac agtttttata ccaaactgtg cctaaaagtc tgtgtctgac cacaagccac
5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataactgat

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaatata gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcaactgcatg aataaaatta ttcttttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 tttgatttct gaccttgtag ctctctttga tggtaacat aatggaagag attctggcta
5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U91835
NID        gl899258
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   source
            Location/Qualifiers
            1..1635
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            CDS
            80..1273
            /note="membrane-tethered chemokine module"
            /codon_start=1
            /product="CX3C chemokine precursor"
            /db_xref="PID:gl899259"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT
FEKQIGEVKPRTPPAAGGMDESIVLEPEATGESSSLEPTSSQEAQRALGTSPELPTG
VTGSSGTRLPTTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
PSTQDPSTQASTASSPAPEENAPSEGRVWVGQGSPPRPNLSLREEMGPVPAHTDAFQ
DWGPGSMAHVSVPVSSEGTPSREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA
QAATRRQAVGLLAFLGLFLFCLGVAMFTYQSLQGCPKRMAGEMAEGLRYIPRSCGSNSY
            sig_peptide      80..151
            mat_peptide     152..1270
            /product="CX3C chemokine"
            misc_feature    152..379
            /note="encodes chemokine module"
            misc_feature    380..1102
            /note="encodes glycosylation stalk"
            misc_feature    1103..1159
            /note="encodes transmembrane helix"
            misc_feature    1160..1270
            /note="encodes intracellular domain"
            3'UTR           1274..1635
            /note="alternatively spliced; long transcript can be

```

found

in GenBank Accession Number U84487"

BASE COUNT

338 a 544 c 464 g 289 t

ORIGIN

```

1  ggcacgaggg cactgagctc tgccgectgg ctctagccgc ctgectggcc cccgccggga
61  ctcttgccca ccctcagcca tggtccgat atctctgtcg tggctgctcc gcttggccac
121 ctcttgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cactgacagc aagatgacat caaagatacc ttagcttttg ctatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcaatcat ctggagagcg agacagcaca ggtgtttctg
301 tgcgaccctg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgccttaact cgaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
421 cacccttgcc gccgggggaa tggacgagtc tgggttcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttcttc ccaggaagca cagagggccc tggggacctc
541 ccagagctg cgcagggcg tgaactgttc ctacgggacc aggtccccc cgacgccaaa
601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgctcccg tctccactgc
661 cgcacgtgg cagagttctg ctccccacca acctgggccc agcctctggg ctgaggcaaa
721 gactctctag gccccgtcca ccaggagccc ctccaccag gcctccactg cgtcctcccc
781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 ctccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg accctaagg ctgaggaacc
1021 catccatgcc accatggacc ccagaggct gggcgtcctt atcactcctg tccctgacgc
1081 ccaggctgcc acccgagggc aggcggtggg gctgctggcc ttccttggcc tctctctctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccgagctgtg ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactctc tggcctgtgt ctagtgttt gattcagaca gctgctggg
1321 atccctcatc ctcatacca cccccacca agggcctggc ctgagctggg atgattggag
1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagctc ccaggcattc ccaggaggc
1441 cagccttgac cattctccac ctccaggga cagaggggt ggctcccaa ctcacccag
1501 ccccaaaact ctctctgct gctggctggt tagaggttc ctttgacgcc atccagccc
1561 caatgaacaa ttatttatta aatgcccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaaa

```

//

```

LOCUS      HSU84487      3310 bp      mRNA      PRI      15-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U84487
NID        g1888522
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 3310)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 3310)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (07-JAN-1997) Molecular Biology, DNAX Research
            Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   Location/Qualifiers
            source          1..3310
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
            CDS             80..1273
                               /note="membrane-tethered chemokine module"
                               /codon_start=1
                               /product="CX3C chemokine precursor"
                               /db_xref="PID:g1888523"

```

/translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP

VALLIHYQQNQASCGKRAIILETRQHRFLFCADPKEQWVKDAMQHLDRQAAALTRNGGT

FEKQIGEVKPRTPPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
 VTGSSGTRLPPTPKAQDGGPVGTFLFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
 PSTQDPSTQASTASSPAEENAPSEGQRVWVGQGSPPRPNLSLREEMGPVPAHTDAFQ
 DWGPGSMAHVSVPVSSEGTSPREPASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLLFCLGVAMFTYQSLQGCPRKMAGEMAELRYIPRSCGSNSY

VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 misc_feature /product="CX3C chemokine"
 152..379
 misc_feature /note="encodes chemokine module"
 380..1102
 misc_feature /note="encodes glycosylation stalk"
 1103..1159
 misc_feature /note="encodes transmembrane helix"
 1160..1270
 misc_feature /note="encodes intracellular domain"
 3'UTR 1274..3310
 /note="alternatively spliced; short transcript

deposited

as GenBank Accession Number U91835"

BASE COUNT 659 a 1051 c 916 g 682 t 2 others
 ORIGIN

```

1 ggcacgaggg cactgagctc tgcgcctgg ctctagccgc ctgcctggcc cccgcgggga
61 ctcttgccca cctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 ctcttgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cactgtcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcaatcat ctgggagacg agacagcaca ggctgttctg
301 tgcgacccg aaggagcaat ggttcaagga cgcgatgcag catctggacc gccaggctgc
361 tgcctaaact cgaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
421 cacccttgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaa cccaggcgga
481 aagcagtagc ctggagccga ctcttcttc ccaggaagca cagaggggcc tggggacctc
541 cccagagctg ccgacgggcg tgactggttc ctacagggacc aggcctcccc cgacgcaaaa
601 ggctcagga ggagggcctg tgggcacgga gcttttccga gtgcctcccg tctccactgc
661 cgccacgtgg cagagtcttg ctccccacca acctggggccc agcctctggg ctgaggcaaa
721 gacctctgag gccccgtcca cccaggaccc ctccaccagc gcctccactg cgtctcccc
781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 cttccaggac tgggggctcg gcagcatggc ccacgtctct gtggtccctg tctctcaga
961 agggaccccc agcaggagc cagtggcttc aggcagctgg acccctaagg ctgaggaaac
1021 catccatgcc accatggacc cccagaggtt gggcgctcct atcaactcctg tccctgacgc
1081 ccaggctgcc acccggaggc aggcgggtgg gctgctggcc ttccttggcc tctcttctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactcttc tggcctgtgt ctagtgtttt gattcagaca gctgcctggg
1321 atccctcctc ctcatacca ccccccacca agggcctggc ctgagctggg atgattggag
1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
1441 cagccttgac cattctccac cttccaggga cagagggggt ggccctccaa ctcacccag
1501 ccccaaaact ctctctgtg gctggctggg tagaggttcc ctttgacgcc atccagccc
1561 caatgaacaa ttatttatta aatgccagc cccttctgac ccatgctgcc ctgtgagtac
1621 tacagtcctc ccattctcaca catgagcacc agggcaggcc ctctgcccac tccctgcaac
1681 ctgattgtgt ctcttggtcc tgcctgagtt gccagtcacc ccggccacct gcggtgctat
1741 ctccccagc cccatctctt gtacagagcc cagcccccga ctggtgacat gcttttctt
1801 gcatgaggct agtgtgtgtt ttcctgggca ctgcttccag tgaggctctg ccttgggtta
1861 ggsattgtgg gaaggggaga taagggtatc tgggtgactt cctctttgtt ctacactgtg
1921 ctgagtctga aggtctgggt ctgattctag ttcaccatac aagccaccaa catactcca
1981 tctgtgaaag gaaagaggga ggttaaggaat acctgtcccc ctgacaacac tcattgacct
2041 gaggcccttc tctccagccc ctggatgcag cctcacagtc cttaccagca gaggcactta
2101 gacagtccct gccaatggac taacttgctc ttggaccctg agggccagag ggcctgcarg
2161 ggagttagtt gatagcacag accctgccct gtgggcccc aaatggaaat gggcagagca
2221 gagaccatcc ctgaaggccc cgcccaggct tagtactga gacagccgg gctctgctc
2281 ccatcacccg ctaagaggga gggagggtc cagacacatg tccaagaagc ccaggaaagg
2341 ctccaggagc agccacatc ctgatgcttc ttcagagact cctgcaggca gccaggccac
2401 aagacccttg tgggtccacc ccacacagc cagattcttt cctgaggctg ggtctccctc
2461 ccacctctct cactccttga aaacactgtt ctctgcccct caagaccttc tcttccact
2521 ttgtccccc cgcagacagg accaggggat ttccatgatg ttttccatga gtccctgtt
2581 tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagtgtga

```



```

2641 ggcataaagt caggggttcc cttttttggc tgctgaaggc tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggc gctcacctct cccttggtatt
2761 gtccccgacc cttgctgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ccttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaacg ctgtgctgcc ctgccacccc tggcctctgc actccccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctcaggtggg gtcactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gagcctttca
3061 ggggtggggac accctgtgat ggggccctgc ctccctttgt aggaagccgc tggggccagt
3121 tgggtccccct tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact ttccaacccc tcatcaccaa
3241 cgtctgtgcc atttgttatt ttactaataa aatttaaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
            cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL     Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES
            Location/Qualifiers
            source
            1..1430
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /chromosome="17"
            gene
            1..1430
            /gene="HCC-4"
            CDS
            1..363
            /gene="HCC-4"
            /note="CC or beta chemokine family member"
            /codon_start=1
            /product="IL-10-inducible chemokine"
            /db_xref="PID:g2581781"

```

/translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNTPTSCCLKYYEK

```

VLPRRLVVG YRKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYIKDNLPLLPTRNLS
TVKIITAKNGQPQLNSQ"

```

```

BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN

```

```

1 atgaaggctt cagaggctgc cctgtctctc cttgtctcca tccttatcat tacttcggct
61 tctcgagccc agccaaaagt tcttgagtgg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gagcactggg tccaagagta catcaaggat cccaacctac ctttctgccc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatgggtcaac cccagctctc caactcccag
361 tgatgaccag gcttttagtg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattaggc tgaaactagc cagtcaacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct tctcaatctt aggaggaagt accaaagtta
541 agggacgtgg gcagaggtag gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcacc caggctggag gcagtgggtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gctcccagag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt ttttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggc tcaaactcgt gtgcccacga aatcccactg
841 cctcagcctt ccaaaaagtg tgggattaca ggctgagacc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctctctg ctctctttta attcctcact

```

961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tctgtgccat
1081 ctttatggat tttcttgat ctatatcttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

//

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents	* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.